

CURRICULUM VITAE*



NAME **W. Archie Bleyer, MD, FRCP[Glasg]**

PRESENT TITLES Clinical Research Professor, Radiation Medicine, The Knight Cancer Institute
Cross-Appointed Research Faculty, † **Oregon Health & Science University**, Portland
Professor of Pediatrics, **McGovern Medical School, The University of Texas**
Senior Advisor, Children's Oncology Group Adolescent and Young Adult Cancer Committee
Collaborator, Institute of Health Metrics and Evaluation, **University of Washington**

IMMEDIATE PAST TITLES Medical Director, Clinical Research and Chair, Institutional Review Board,
St. Charles Healthcare System, Central | Eastern Oregon

CITIZENSHIP United States of America

HOME ADDRESS AND OFFICE 2884 NW Horizon Dr. **Telephone:** 541-610-4782
Bend, Oregon 97703 **Cell:** 541-610-4782

EMAIL ADDRESS ableyer@gmail.com

WEBSITES creator and manager: www.comedsoc.org www.stcharlesresearch.org (defunct)

WEB BIOSKETCH <https://www.ohsu.edu/school-of-medicine/radiation-medicine/archie-bleyer-md>

EDUCATION

1961-1965	B.S. in Life Sciences, Massachusetts Institute of Technology , Cambridge, Massachusetts
1963-1965	Thesis: 24/7 renal physiology in the ambulatory rat Leonard Kleinman, MD, Edward Radford, MD, Harvard School of Public Health
1965-1969	M.D., University of Rochester School of Medicine and Dentistry , Rochester, New York
Postgraduate Training	1969-1970 Internship (Medicine-Pediatrics), University of Washington and Children's Hospital and Medical Center, Seattle, Washington
	1970-1971 Residency in Pediatrics, University of Washington Hospital and Children's Hospital and Medical Center , Seattle, Washington
	1971-1974 Clinical Associate, Laboratory of Chemical Pharmacology and Attending Physician, Pediatric Branch, National Cancer Institute , Bethesda, Maryland
	1974-1975 Senior Fellow, Hematology/Oncology, Seattle Children's Hospital , Seattle, Washington
	1984-1986 Fellow, Radiation Oncology, University of Washington , Seattle, Washington

NOBEL LAUREATE MENTORS **Vernon Ingram**, PhD, Massachusetts Institute of Technology
Salvador Luria, PhD, Massachusetts Institute of Technology
E. Donnell Thomas, MD, Fred Hutchinson Cancer Research Center

CREDENTIALS

Board and Other Certifications	National Board of Medical Examiners Examination, July 1, 1970 American Board of Pediatrics, June 1, 1975, Certificate #18103 Pediatric Hematology-Oncology, American Board of Pediatrics, June 1, 1976, Certificate #217 Recertified in Pediatrics and in Pediatric Hematology-Oncology, May 9, 1986, Certificate #217 Certified in Pediatric Advance Life Support, January 19, 1996 National Cancer Institute Investigator No. 5105
Licensure Inactive	States of Washington (License 11608 1970-1990), Texas (License H7391 1990-2007), and Oregon, License No. (License MD26481 2005-2017)

* Abbreviated with year 2000+ for most categories; full CV available upon request

† <https://www.ohsu.edu/school-of-medicine/radiation-medicine/archie-bleyer-md>

EXPERIENCE / SERVICE

Military Service	July 1, 1971 - May 15, 1974	United States Public Health Service, NIH, NCI, Bethesda, Maryland Assistant Surgeon (Lieutenant Commander)
Academic Appointments:	1975-1978	Assistant Professor of Pediatrics and Adjunct Assistant Professor of Medicine, University of Washington; Assistant Member, Fred Hutchinson Cancer Research Center, Seattle, Washington
	1978-1983	Associate Professor of Pediatrics and Adjunct Associate Professor of Medicine, University of Washington; Associate Member, Fred Hutchinson Cancer Research Center, Seattle, Washington
	1979-1983	Adjunct Associate Professor of Radiation Oncology, University of Washington, Seattle, Washington
	1982-1990	Director, Jennifer Sacco Research Laboratories, Children's Hospital and Medical Center, Seattle, Washington
	1983-1990	Professor of Pediatrics , University of Washington; Adjunct Professor of Medicine & Radiation Oncology , University of Washington; Full Member , Fred Hutchinson Cancer Research Center; Seattle, Wash.
	1984-1990	American Cancer Society Professor of Clinical Oncology , University of Washington, Seattle, Washington
	1990-1999	Head, Division of Pediatrics, and Chair, Department of Pediatrics , The University of Texas M. D. Anderson Cancer Center, Houston, Texas
	1990-1999	Head, Division of Hematology/Oncology, Department of Pediatrics , The University of Texas Medical School, Houston, Texas
	1990-2004	Professor of Pediatrics , The University of Texas M. D. Anderson Cancer Center, Houston, Texas
	2000-2004	Director, Community Oncology , Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
	1996-1998	Instructor, ASCO/AACR Workshops on Clinical Trials, Vail, Colorado
	1990-	Professor of Pediatrics , McGovern Medical School, The University of Texas, Houston, Texas
	2005-	Clinical Research Professor , Oregon Health and Science University, Portland, http://www.ohsu.edu/xd/education/schools/school-of-medicine/departments/clinical-departments/radiation-medicine/about/faculty-staff/archie-bleyer.cfm
	2006-	Chair, Data Safety Monitoring Committee , Blood Brain Barrier Consortium, Department of Neurosurgery, Oregon Health & Science University
	2007-	Senior Advisor and Health Services Research Collaborator , Cancer Medicine, Knight Cancer Institute, Oregon Health and Science University
Trainee Mentorships:	2008-2023	<i>Kristin Bingen, PhD</i> , Assist. Prof. Pediatrics, Medical College of Wisconsin <i>Melissa Y. Carpentier, PhD</i> , Indiana University School of Medicine <i>Jennifer McNeer, MD</i> , Dept. Pediatrics, University of Chicago <i>Ally Gallagher</i> , Oregon Health and Science University Medical Student <i>Kayo Nakata-Yamada</i> , Assistant Section Chief, Center for Cancer Control and Statistics, Osaka Medical Center for Cancer and Cardiovascular Diseases <i>Frank Chien</i> , Medical Student, Jefferson Medical College <i>Rebecca Johnson, MD</i> , Assistant Professor of Pediatrics, University of Washington <i>Altan Manai, MD</i> , Fellow, Hemat/Oncol, University of Miami School of Medicine <i>Nicholas G. Zaorsky, MD MS</i> , Assistant Professor, Departments of Radiation Oncology and Public Health Science, Penn State College of Medicine <i>Kelsey Corrigan, MD</i> , Fellow, Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center

Renata Abrahao, PhD, Research Assistant, Department Health Care Policy & Research, and Internal Medicine - Division of Hematology/Oncology, University of California Davis Medical Center

Hospital Appointments:	1975-1990	Staff Physician, Children's Hospital and Medical Center, Seattle, Washington
	1995-2001	Medical Staff, Hermann Hospital, Houston, Texas
	1995-1997	Medical Staff, Northwest Texas Healthcare System, Amarillo, Texas
	2005-2011	Medical Director, Clinical Research , St. Charles Cancer Treatment Center, Bend, Oregon
	2006-2014	Chair, Institutional Review Board , St. Charles Healthcare System, Central Eastern Oregon
Medical Associations	2006-2008	Oregon Medical Association (OMA #27244)
	2005-	Central Oregon Medical Society
	2015-2017	Board of Directors, Oregon Society of Medical Oncology

HONORS AND AWARDS

1964-1964	Treasurer and Executive Assistant, Interfraternity Council and Alpha, Chi Phi Fraternity, Massachusetts Institute of Technology
1969	M.D. "with honor and with distinction in research" , University of Rochester School of Medicine and Dentistry
1969	Collier Prize for "compassionate and understanding care of the sick," University of Rochester School of Medicine and Dentistry
1969	Obstetrics-Gynecology Award for Scholarship, University of Rochester
1971	Resident's Prize, North Pacific Pediatric Society
1975-1978	Junior Faculty Clinical Fellowship Award, American Cancer Society
1976-1979	Faculty Development Award in Clinical Pharmacology, Pharmaceutical Manufacturers Association Foundation
1978-1983	Scholar Award, Leukemia Society of America
1984-1990	American Cancer Society Professor of Clinical Oncology , University of Washington School of Medicine
1990-2003	Mosbacher Pediatrics Chair, The University of Texas MD Anderson Cancer Center, Houston, TX
1992	The Best Doctors in America 1992-1993 , Naifeh S, Smith GW, Woodward/White, Aiken, SC
1992-2002	Chair, Children's Cancer Group
1994	The Best Doctors in America, 1994-1995 Naifeh S, Smith GW, Woodward/White, Aiken, SC
1994	1st Place, International Health and Medical Film Festival, Category of Patient Care for "Mending Spirits: Children after Cancer" (Greichen L, Ed.)
1996	Re-Elected Chair, Children's Cancer Group
1997	The Best Doctors in America: Central Region, 1996-1997 Woodward/White, Aiken, SC
1998	Mark E. Nesbit Lecturer, University of Minnesota
1998	Robert M. Heavenrich Lecturer, Michigan State University
1998-2001	Faculty, ASCO/AACR Workshops on Clinical Trials, Vail, Colorado
1998-2004	Top Doctors in Houston, Inside Houston, 1998, 2002
1999	Partners in Courage Award, American Cancer Society
2000	Amanda Toll Lecturer, Children's Hospital National Medical Center, District of Columbia
2000	Nitschke-Kaskaske Lecturer, University of Oklahoma Department of Pediatrics, Oklahoma City
2000	Irene Lefton Memorial Lecture, North Shore University Hospital, Long Island, New York
2000	National Registry, Who's Who 2000 (Designated Life Member)
2001	Children's Oncology Group Legacy Award
2001	Burkholder Lecture, Mountain States Tumor Institute, Boise, Idaho
2001	1st Aflac Children's Cancer Center Visiting Professor, Children's Healthcare of Atlanta, Emory University and Egleston Children's Hospital, Atlanta
2001	10th Felix Feldman Lecturer, Maimonides Medical Center, New York, New York

- 2001 5th Annual Henry and Eleanor Carlson Lecturer, University of South Dakota School of Medicine, Sioux Falls, South Dakota
- 2001 Honored Member in America's Registry of Outstanding Doctors, 2000-2003
- 2002 21st Century Award for Achievement, International Biographical Centre, Cambridge, England
- 2003-2004 Mosbacher Pediatrics Chair Emeritus,
The University of Texas MD Anderson Cancer Center, Houston, Texas
- 2001-2005 **America's Top Doctors, Castle Connolly Guide, 2001, 2002, 2003, 2004**
Only University of Texas M.D. Anderson Cancer Center Pediatrician Listed
- 2004-2005 America's Top Pediatricians, Consumers' Research Council of America, Washington D.C.
- 2005 **Leading Health Professionals of the World**, International Biographical Centre, Cambridge, England
- 2005 **Living Wellness Award**, The Wellness Community, Washington D.C.
- 2005 **Melissa Living Legacy Foundation Award**, Teens Living with Cancer
- 2006 **Distinguished Career Award**, American Society of Pediatric Hematology and Oncology
- 2009 Elected **President, Central Oregon Medical Society**
- 2011 **Member Commitment Award**, LiveStrong Young Adult Alliance
- 2014 **Dr. Archie Bleyer Adolescent and Young Adult Trailblazer Award**, Critical Mass Young Adult Cancer Alliance, initiating annual awards
- 2015 **Special Recognition Award**, American Society of Clinical Oncology
- 2015 University of Rochester School of Medicine & Dentistry **Distinguished Alumnus Award**
- 2015 Children's Oncology Group **Archie Bleyer Aflac Young Investigator Award in Adolescent and Young Adult Oncology**, initiating annual awards
- 2016 **Founders Award**, The Ulman Fund for Young Adults with Cancer
- 2015 Elected to **Board of Directors**, Oregon Medical Oncology Society
- 2017 **Global Adolescent and Young Adult Cancer Congress Archie Bleyer Trailblazer Award**, initiating biennial awards
- 2017 Director, Pease/Pariser 2-Day Symposium for Health Professionals and Spouses:
Operation Stress Removal, Bend, Oregon

LECTURESHIPS AND VISITING PROFESSORSHIPS

- 1984 First James Whitcomb Riley Visiting Professor, Indiana University, Indianapolis, Indiana
- 1985 John A. Burns School of Medicine Visiting Professor, Department of Pediatrics, University of Hawaii, Honolulu, Hawaii
- 1985? Jennie ? Memorial Lectureship, Royal Alexandra Hospital for Children, New South Wales, Australia
- 1986 Visiting Professor, University of North Carolina, Departments of Pediatrics and Pathology, Chapel Hill, North Carolina
- 1986 Visiting Professor, Medical College of Georgia, Department of Pediatrics, Augusta, Georgia
- 1986 Visiting Professor, Vanderbilt University, Departments of Neurology and Pediatrics, Nashville, Tennessee
- 1986 Visiting Professor, Children's Hospital of Los Angeles, University of Southern California, Los Angeles
- 1986 Visiting Professor, St. Louis University, Department of Pediatrics, St. Louis
- 1986 Visiting Professor, University of Chicago School of Medicine, Departments of Medicine and Pediatrics, Wyler Children's Hospital, and Michael Reese Hospital and Medical Center, Chicago, Illinois
- 1987 Visiting Professor, Ohio State University School of Medicine, Department of Pediatrics, Children's Hospital, Columbus, Ohio
- 1987 Visiting Professor, University of Rochester Departments of Radiation Oncology & Pediatrics, Rochester, New York
- 1987 Visiting Professor, University of Nijmegen, Institute of Pediatrics and Sint Radboud Hospital, Nijmegen, Netherlands
- 1987 Visiting Professor, Dana Farber Cancer Institute, Departments of Medical and Pediatric Oncology, Boston
- 1988 Visiting Professor, Loma Linda University, Departments of Pediatrics and Neurosurgery, Loma Linda, California
- 1988 Consultant and Seminar Participant, Preuss Foundation
- 1989 Visiting Professor, Children's Hospital of Orange County, Orange County, California
- 1990 Visiting Professor, Johns Hopkins University, Johns Hopkins Cancer Center, Baltimore, Maryland
- 1990 Visiting Professor, New York University Medical Center, Departments of Pediatrics and Medicine, NYC
- 1990 Visiting Professor, Columbia River Oncology Program, Portland, Oregon

- 1991 Visiting Professor, Orlando Regional Cancer Center, Orlando
- 1991 Lecturer, Tomorrow Children's Institute Continuing Education Course, Orlando
- 1991 Visiting Professor, Department of Pediatrics, Stanford University Medical School, Palo Alto
- 1991 Visiting Professor, University of California at Irvine, Children's Medical Research Found., Orange, California
- 1991 Visiting Professor, Mountain Valley Medical Center, Mountain Valley, California
- 1991 Visiting Professor, Children's Hospital of Northern California, Oakland
- 1991 Visiting Professor, Orlando Cancer Center and Arnold Palmer Hospital for Women and Children
- 1992 Visiting Professor, Yale University Medical Center, New Haven, Connecticut
- 1992 Consultant, University of Vermont Medical Center, Burlington
- 1993 Lecturer, Marshfield Clinic, Marshfield, Wisconsin
- 1993 Visiting Professor, University of Texas Southwestern Medical Center, Dallas, Texas
- 1993 Visiting Professor, Orlando Cancer Center and Arnold Palmer Children's Hospital
- 1993 Extramural Advisory Committee, Duke University Comprehensive Cancer Center
- 1993 Extramural Advisory Committee, Duke University Comprehensive Cancer Center
- 1994 Visiting Professor, University of Iowa, Iowa City, Iowa
- 1998 Mark E. Nesbit Professor, University of Minnesota
- 2000 Nitschke-Kaskaske Visiting Professor, University of Oklahoma Department of Pediatrics, Oklahoma City
- 2000 Visiting Professor, North Shore University Hospital, Schneider Children's Hospital, and Long Island Jewish Hospital, New York
- 2001 Burkholder Lecture, Mountain States Tumor Institute, Boise, Idaho
- 2001 10th Felix Feldman Lecturer, Maimonides Medical Center, New York
- 2001 1st Aflac Children's Cancer Center Visiting Professor, Emory University, Atlanta
- 2004 Ludvina Knapp Memorial Lecturer, Children's Mercy Hospital, Kansas City, Kansas
- 2004 2nd Ronald L. Chard, Jr., Memorial Lecturer, Children's Hospital Regional Medical Center, Seattle
- 2005 Mayo Clinic Oncology Society Distinguished Speaker, Rochester, Minnesota
- 2005 Meet the Expert Survivorship Presenter, ASCO, 41st Annual Meeting, Orlando, Florida

[2006+ Only special distinctions recorded]

- 2007 Inaugural Speaker: Katie Miller Young Adult Cancer Conference. Des Moines University, Des Moines, Iowa
- 2011 Keynote Speaker, Nordic/Baltic Pediatric Hematology-Oncology Organization (NOPHO), Torcu, Finland
- 2011 Keynote Speaker, Puerto Rico Hematology-Oncology Association
- 2011 Inaugural Speaker: Disney Family Cancer Center AYA* Cancer Program, Burbank, California
- 2013 Planner and Host: *The challenge of overdiagnosis in population screening for disease*. Pease Symposium. Riverhouse Convention Center, Bend, Oregon
- 2013 Inaugural Speaker: Angie Fowler AYA* Clinic, University Hospital, Cleveland and Rainbow Babies Children's Hospital, Cleveland
- 2013 Founding Member, Critical Mass Young Adult Cancer Alliance
- 2013 Inaugural Speaker: David Stroud AYA* Program, University of Southern California,
- 2014 Plenary Presentation: *Adolescents and Young Adults with Cancer: Unique Biology?* International Society of Clinical Oncology Annual Meeting, Toronto, Canada, October 2014.
- 2014 Inaugural Speaker: Reid Sacco AYA* Clinic, Tufts University Medical Center, Boston
- 2014- St. Charles Healthcare System Grand Rounds, Central/Eastern Oregon: Various topics, including screening mammography, pandemic collateral mortality, clinical trials in Central Oregon, medical professionals' wellness, ...
- 2015 Special Recognition Award, ASCO Annual Meeting: History of AYA Oncology, Chicago
- 2017 Host: Pease/Pariser *Operation Stress Removal* 2-Day Conference, Bend, Oregon
- 2018 Sarah Weinberg Lecture: *Surviving Cancer during early Adulthood*. University of Chicago
- 2019 Teen Cancer Monthly Drip [Decreasing Life Expectancy of Americans](#).
- 2021 Acute Leukemia Forum 2021 Plenary Session: *Important Factors Improving Outcome of Young Adults with Acute Lymphoblastic Leukemia*. April 8, 2021.
- 2021 Northeast AYA* Cancer Conference Keynote Speaker: *Brief History of the AYA Cancer Movement*. April 9, 2021.

* AYA – adolescent and young adult

INSITUTIONAL SERVICE**Academic Administrative Appointment/Responsibilities**

- 1975-1990 Children's Cancer Group (CCG): Chair, Low-Risk Acute Lymphoblastic Leukemia Study CCG-161
 1975-1978 Chair, VM-26 Phase II Study Committee, CCG*
 1976-1979 Children's Hospital and Medical Center (CHMC) Tumor Clinic: Associate Director
 1978-1982 Chair, Brain Tumor Strategy Group, CCG*
 1979-1982 CoEditor, Pharmacy Script, CHMC°
 1980-1987 American Board of Pediatrics Sub-Board in Pediatric Hematology-Oncology
 1980-1984 Chair, Pharmacy and Therapeutics Committee, CHMC°
 1980-1989 Associate Chair, Leukemia and Lymphoma Studies, Children's Cancer Group
 1982-1986 Chair, Acute Lymphoblastic Leukemia Strategy Group, Children's Cancer Group
 1983-1990 Director, Jennifer Sacco Research Laboratories, CHMC°
 1985 Co-Chair, Biennial Meeting, Professors of Clinical Oncology, American Cancer Society (ACS)
 1985-1987 Chair, Professional Education Committee, Washington Division, ACS†
 1986-1989 Associate Chair, New Agents and Pharmacology Studies, Children's Cancer Group
 1987-1991 National Board of Directors, Medical Director-at-Large, ACS†
 1988-1990 Program Director, ACS Clinical Oncology Fellowship Training Program, CHMC2
 1988-1989 Chair, Neuropsychologic Sequelae after Pre-Irradiation Methotrexate in Childhood Acute Lymphoblastic Leukemia study CCG-Q881, Children's Cancer Group
 1989 Chair and Co-Coordinator, International Symposium on Pediatric Neuro-Oncology, Premier Session, Seattle
 1989-1991 Vice-Chair, Task Force on Children and Cancer, ACS†
 1989-1991 Vice Chair, Children's Cancer Group
 1989-1992 Chair, Publications Committee, Children's Cancer Group
 1990 Co-Coordinator, International Symposium on Pediatric Neuro-Oncology, Philadelphia
 1990-1996 Chair, Pediatric Facilities Planning Committee, University of Texas MD Anderson Cancer Center (UTMDACC)
 1990-1994 Chair, Pediatrics Reimbursement Committee, UTMDACC+
 1990-1992 Principal Investigator, Children's Cancer Group
 1991-1992 Chair-Elect, Children's Cancer Group
 1991-1992 Co-Chair, United Way Campaign, Patient Care, UTMDACC+
 1991-1993 Chair, Clinical Trainees Research Project Competition Subcommittee, UTMDACC+
 1991-1994 Chair, Texas Outreach Committee, Physician Referral Service, UTMDACC+
 1992-1994 Coordinator, International Symposium on Pediatric Neuro-Oncology, Houston
 1992 Chair, Search Committee, Head, Division of Diagnostic Imaging (Departments of Diagnostic Radiology and Nuclear Medicine), UTMDACC+
 1992-2002 **Chair, Children's Cancer Group**
 1993-1994 Medical Advisory Board, PediatriCare America
 1993 Chair, Data Monitoring Committee, Children's Cancer Group
 1993-1999 Chair, Research Committee, Physicians Referral Service, UTMDACC+
 1994-1995 Chair, Conscious Sedation Steering Committee, UTMDACC+
 1994-1999 Chair, Scientific Review Committee, Physicians Referral Service, UTMDACC+
 1994-1995 Children's Cancer Group: Co-Chair, Long Range Planning Committee, National Childhood Cancer Foundation, Arcadia, California
 1995 Coordinator and Co-Chair, U.S.-Japan Symposium on Pediatric Oncology, Nagoya
 1996 Coordinator, International Symposium on Pediatric Neuro-Oncology, Washinton, D.C.
 1996-1997 Coordinator and Co-Chair, U.S.-Japan Symposium on Pediatric Oncology, Houston
 1997 **Re-Elected Chair, Children's Cancer Group**
 1997 Founder, Adolescent and Young Adult Oncology program, UTMDACC+
 1998 Chair, Physician Referral Service Clinical Research Committee, UTMDACC+
 1998 Chair, Faculty Celebration Entertainment Subcommittee, UTMDACC+

*CCG - Childrens Cancer Group

°CHMC - Children's Hospital and Medical Center, Seattle, Washington

†ACS - American Cancer Society

+ UTMDACC - The University of Texas M.D. Anderson Cancer Center

1999-2000 Faculty Co-Chair, Faculty Celebration Committee, UTMDACC⁺
 1999 Chair, Physician Referral Service-Children's Art Project Patient-Oriented Research Committee, UTMDACC⁺
 2000-2005 Chair, Adolescent and Young Adult Committee, Children's Oncology Group (COG)
 2000-2004 Director, Community Clinical Oncology Program, UTMDACC⁺
 2001-2008 Chair, International Collaboration and Foreign Membership Committee, Children's Oncology Group
 2001-2005 Chair, Data and Safety Monitoring Board, North American Brain Tumor Consortium
 2005-2013 Founding Member, LiveStrong Young Adult Alliance
 2005 Chair, International Society of Pediatric Oncology (SIOP) Adolescent and Young Adult Organizing Committee
 2003-2007 Chair, PlanetCancer* Medical Advisory Board
 2007-2008 Chair, ASCO[§] Patient Communication Subcommittee
 2006-2012 Associate Editor, Adolescent and Young Adult Oncology, Journal of Pediatric Hematology-Oncology
 2008 Co-Chair, LiveSTRONG Young Adult Alliance Institutional Review Board (IRB) Committee
 2004-2013 Director, Aflac/CureSearch Adolescent and Young Adult Cancer Research
 2011-2014 Chair, Scientific Review Committee, St. Charles Healthcare System, Central Oregon
 2012-2014 Co-Chair, Center for Disease Control Initiative in Improving Enrollment of Adolescents on Cancer Clinical Trials
 2012-2014 Co-Chair, National Cancer Institute Adolescent and Young Adult Science Working Group on Epidemiology
 2013-2014 Member, St. Charles Healthcare System Executive Values Analysis Committee
 2010-2014 Member, SARC Spore (NIH sarcoma grant) External Advisory Committee
 2005- Oregon Health & Science University Data Safety Monitoring Board, Phase I & II Trials, Dept. of Neurosurgery
 2010- Editorial Board, Journal of Adolescent and Young Adult Oncology

Other Organizational Activities and Appointments/Responsibilities since 2000[†]

1998-2003 National Dialogue on Cancer (President Bush Committee, currently known as C-Change)
 2000-2002 Convocation/Renaissance Committee, UTMDACC⁺
 2000 Special Emphasis Panel (Study Section), Cancer Control and Prevention, Division of Cancer Prevention, NCI
 2000 Professional Liability Committee, UTMDACC⁺
 2001 Research Committee, Division of Pediatrics, UTMDACC⁺
 2001-2004 Advisory Committee for Shared Resources, UTMDACC⁺
 2001-2002 CORE Advisory Committee, UTMDACC⁺
 2001-2003 Neurofibromatosis Research Group, UTMDACC⁺
 2002-2003 Fellowship Applicant Interview Committee, Division of Cancer Medicine, UTMDACC⁺
 2002-2003 Faculty Achievement Award- Clinical Research, UTMDACC⁺
 2001-2004 Division of Cancer Medicine Executive Council, UTMDACC⁺
 2002-2004 Cancer Center Support Grant Biostatistics Review Group, UTMDACC⁺
 2000 ASCO*/American Association for Cancer Research Methods in Clinical Cancer Research Program Committee
 2000 Blue Ribbon Committee on Ascending Neuropathy After Intrathecal Chemotherapy Meeting, NCI and FDA
 2000-2006 Senior Consultant, International Consortium for Cure of Childhood Cancer in China (CURE)
 2000-2003 Special Emphasis Panel (Study Section), Cancer Control and Prevention, Division of Cancer Prevention, NCI
 2001-2005 Chair, International Collaboration and Foreign Membership Task Force, Children's Oncology Group (COG)
 2001-2004 Pediatrics Task Force, Cancer Education Committee, ASCO[‡]
 2001-2002 Peer Review Committee, Children's Oncology Group (COG)
 2001-2002 Governance and Structure Task Force, ASCO
 2001-2004 Publications Committee, ASCO
 2001-2002 Scientific Advisory Board, The Effects of Radiotherapy on Brain and Behavior, Children's Hospital of Philadelphia and University of Pennsylvania
 2002-2004 Strategic Planning Subcommittee, Publications Committee, ASCO
 2002-2005 Sarcoma Committee, Southwest Oncology Group
 2003-2005 Health Disparities Planning Committee, Texas Medical Center
 2003-2004 Roche Pediatric Advisory Board
 2003-2005 Neuropsychological, Cancer Control, and Chronic Disease Working Groups, Childhood Cancer Survivors Study
 2003-2006 Group Loop Professional Advisory Committee, The Wellness Community

*Internet-based support organization for young adults with cancer

[†]Full CV available upon request

[‡]ASCO – American Society of Clinical Oncology

⁺UTMDACC - The University of Texas M.D. Anderson Cancer Center

- 2004-2006 Pediatric Oncology Group of Ontario Research Unit Advisory Committee
 2004-2005 *Lance Armstrong Foundation* Grant Review Committee – Adolescent and Young Adult Programs
 2005-2006 Survivorship Task Force, ASCO*
 2005-2006 Editorial Board, ASCO* *Clinical Cancer Advances* 2006
 2005-2012 *LiveStrong Young Adult* Alliance Organizing Committee
 2005-2008 *Young Survival Coalition* Medical Education Symposium Planning Committee
 2005-2008 Cancer Communications Committee, ASCO*
 2005-2008 Advisory Board, *Waiting Room Magazine: Cancer Uncensored; Changing the Way you See Cancer*
 2007-2008 *Robert Michael Educational Institute* Clinical Advisory Board
 2004-2009 Medical Advisory Committee, *Fertile Hope Foundation*
 2005-2008 Roster of Cancer Experts, ASCO*
 2005-2007 ASCO† Patient Communication SubCommittee
 2001-2010 *Teenage Cancer Trust* (United Kingdom) Steering Committee
 2005-2009 *Lance Armstrong Foundation* Grant Review Committee – Survivorship Programs
 2007-2010 Founding Member, City Club of Central Oregon
 2005-2013 Board of Directors, Tour des Chutes Foundation, Central Oregon
 2008-2014 Bioethics Committee, St. Charles Medical Center
 2011-2014 Values Analysis Committee, St. Charles Healthcare System, Central Oregon
 2009-2015 Board of Directors, *Cancer Adventures* (www.canceradventures.org)
 2004-2019 National Medical Advisory Board, *I'm Too Young for This* Survivorship Foundation
 2003-2019 *Young Survival Coalition*† Medical Advisory Committee
 2006-2019 National Professional Advisory Board, *The Wellness Community*
 2008-2019 Professional Advisory Board, *Cancer Support Community*
 2008-2011 *First Descents* Medical Advisory Board (www.firstdescents.org)
 2001- *Melissa's Living Legacy Teens Cancer Foundation* (now *13thirty*) Medical Advisory Board
 2005- *Young Adult Canada Cancer* Medical Advisory Board (www.realtimecancer.org)
 2007- Medical Advisory Board, *CanTeen* (Australia)
 2012- Scientific Advisory Board, *CureSearch for Children's Cancer*
 2012- *Teen Cancer America* Medical Advisory Group
 2018- F3 Platform Biologics Scientific Advisory Board (amifostine, AmiGuard)
 2019- Co-Director, International Acute Leukemia Research and Care Network (ALRCaN)
 2020-2022 St. Charles Healthcare System COVID Expert Committee
 2020- Co-Developer, CovidAYAcancer internet resource (www.covidAYAcancerl.org)
 2021- Advisory Committee, *Gun Violence: Public Health Issue*, Oregon Health & Science University- Portland State University
 2022- Institutional Review Board, St. Charles Healthcare System

EDITORIAL BOARDS and JOURNAL REVIEWER since 2010

Editorial Board: Journal of Adolescent and Young Adult Oncology

Journal Reviewer:

NEJM	International J Oncol	Cancer Medicine	IEEE J Biomed Health
Lancet	Ca Chemo & Pharm	Leuk Lymph	Informatics
JNCI	Cancer Treat Rev	Annals Oncol	ESMO Open
J Clin Oncol	Women's Health Issues	Blood Advances	Intl J Breast Cancer
J Ca Epi Bio Prev	CNS Oncology	Intl J Adol Med Health	Cinical Pediatrics
J Ca Surv JAMA	Oncotarget	J Pediat Surg	Biomed Res Intl
British Medical J	Cancer Causes & Control	JAMA Oncol	Public Health Reports
Cancer	J Adol Health	Exp Rev Anticancer Ther	Breast Ca Res & Treatment
Medical Oncology	Jornal de Pediatria	Scientific Report (Nature)	Infection Prevention
Oncogene	Blood Review	Science of the Total	Cancer Control
Pediatr Blood Ca	Thorax	Environment	
J Pediat Hem/Oncol	Int J Prevent Medicine		

*ASCO-American Society of Clinical Oncology

†National organization for support of young women with or at high risk of breast cancer

RESEARCH GRANTS

Extramural Grant Support Dr. Bleyer has received a total of \$87,365,461 Direct Costs as the Principal Investigator of research grants, of which \$75,743,461 was awarded by the National Institutes of Health, \$10,000,000 was for a Texas statewide cancer early detection and prevention research program, and \$1,100,000 for the University of Texas M.D. Anderson Community Oncology Research Base funded by the National Cancer Institute. Other sources include the American Cancer Society, Leukemia and Lymphoma Foundation, Lance Armstrong Foundation, and Pharmaceutical Manufacturers Association Foundation.

OTHER GRANTS since 2005

2007-2010 Principal Investigator, **DEFEATcancer** (www.DEFEATcancer.info)
Lance Armstrong Foundation, \$150,000

PUBLICATIONS

a. Articles in Genuine* Peer-Reviewed Journals

1. **Bleyer WA**, Rosen MG. Meperidine-induced changes in the maternal and fetal electroencephalograms of the guinea pig. *Electroenceph Clin Neurophysiol* 24:249-58, 1968.
2. Rosen MG, **Bleyer WA**. Bidirectional transfer of meperidine across the guinea pig placenta. *Am J Obstet Gynec* 101:918-22, 1968.
3. **Bleyer WA**, Au WY, Lange WA Sr, et al. Studies on the detection of adverse drug reactions in the newborn. I. Fetal exposure to maternal medications. *JAMA* 213:2046-8, 1970.
4. **Bleyer WA**, Breckenridge RT. Studies on the detection of the adverse drug reactions in the newborn. II. The effects of prenatal aspirin on newborn hemostasis. *JAMA* 213:2049-53, 1970.
5. **Bleyer WA**, Hakami N, Shepard TH. The development of hemostasis in the human fetus and newborn. *J Pediatr* 79:828-53, 1971.
6. **Bleyer WA**, Marshall RE. Barbiturate withdrawal syndrome in a passively addicted infant. *JAMA* 221:185-6, 1972
7. Graw RG, Yankee RA, Leventhal BG, et al. Bone marrow transplantation in acute leukemia employing cyclophosphamide. *Exptl Hematol* 22:118-25, 1972.
8. **Bleyer WA**, Drake JC, Chabner BA. Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. *N Engl J Med* 289:770-4, 1973.
9. Duttera MJ, **Bleyer WA**, Pomeroy TC, et al. Irradiation, methotrexate toxicity and the treatment of meningeal leukemia. *Lancet* 2:703-7, 1973.
10. Yancy ST, **Bleyer WA**. Characteristics and response to certain cancer chemotherapeutic agents of an acute lymphocytic leukemia arising in a BALB/c x DBA/2F1 mouse. *Cancer Research* 34:1866-9, 1974.
11. Graw RG, Galnick HR, Henderson ES, et al. Bone marrow transplantation following combination chemotherapy immunosuppression (B.A.C.T.) in patients with acute leukemia. *Transpl Proc* 6:349-54, 1974.
12. Jacobs SA, **Bleyer WA**, Chabner BA, Johns DG. Altered plasma pharmacokinetics of methotrexate administered intrathecally. *Lancet* 1:455-6, 1975.
13. **Bleyer WA**, Blaese RM, Bujak JS, Herzig GP, Graw RG, Jr. Long-term remission from acute myelogenous leukemia after bone marrow transplantation and recovery from acute graft-versus-host reaction and prolonged immuno-incompetence. *Blood* 45:171-81, 1975.
14. **Bleyer WA**, Frisby SA, Oliverio VT. The uptake and binding of vincristine by murine leukemia cells. *Biochem Pharm* 24:633-9, 1975.
15. Bender RA, **Bleyer WA**, Frisby SA, Oliverio VT. Alteration of methotrexate uptake in human leukemia cells by other drugs. *Cancer Res* 35:1305-8, 1975.

* Those that are not “open”, “pay to publish”, “predatory”, profit driven, etc.

16. Dedrick RL, Zaharko D, Bender RA, **Bleyer WA**, Lutz RJ. Pharmacokinetic considerations on resistance to anticancer drugs. *Cancer Chemother Rep* 59:795-804, 1975.
17. Waalkes P, **Bleyer WA**, Jacobs SA, et al. Potential biochemical markers in Burkitt's lymphoma. *Cancer Chemother Rep* 59:721-7, 1975.
18. **Bleyer WA**. Surveillance of pediatric adverse drug reactions - a neglected health care problem. *Pediatrics* 55:308-10, 1975.
19. Pizzo PA, **Bleyer WA**, Poplack DG, Leventhal BG. Reversible dementia temporally associated with intraventricular therapy with methotrexate in a child with acute myelogenous leukemia. *J Pediatr* 88:131-3, 1976.
20. DiChiro G, Hammock K, **Bleyer WA**. Spinal descent of cerebrospinal fluid in man. *Neurology* 26:1-8, 1976.
21. **Bleyer WA**, Skinner AL. Fatal perinatal hemorrhage after maternal anticonvulsant therapy. *JAMA* 235:626-7, 1976.
22. Gutin PH, Green, MR, **Bleyer WA**, Bauer VL, Wiernik PH, Walker MD. Methotrexate pneumonitis induced by intrathecal methotrexate therapy. A case report with pharmacokinetic data. *Cancer* 38:1529-34, 1976.
23. Bender RA, **Bleyer WA**, Drake JC, Ziegler JL. In vitro correlates of clinical response to methotrexate in acute leukemia and Burkitt's lymphoma. *Br J Cancer* 34:484-92, 1976.
24. Wood JH, Poplack DG, **Bleyer WA**, Ommaya AK. Primate model for the chronic study of intraventricularly- or intrathecally-administered drugs and intracranial pressure. *Science* 195:499-501, 1977.
25. Davis RF, Eichner JM, **Bleyer WA**, Okamoto G. Hypocalcemia, hyperphosphatemia and dehydration following a single hypertonic phosphate enema. *J Pediatr* 90:484-5, 1977.
26. Poplack DG, **Bleyer WA**, Wood JH, Kostolich M, Savitch JL, Ommaya AK. A primate model for study of methotrexate pharmacokinetics in the central nervous system. *Cancer Res* 37:1982-5, 1977.
27. **Bleyer WA**, Dedrick RL. The clinical pharmacology of intrathecal methotrexate. 1. Distribution kinetics in nontoxic patients after lumbar injection. *Cancer Treat Rep* 61:703-8, 1977.
28. **Bleyer WA**. Methotrexate: clinical pharmacology, current status and therapeutic guidelines. *Cancer Treatment Rev* 4:87-101, 1977.
29. **Bleyer WA**. Current status of intrathecal chemotherapy for human meningeal neoplasms. *Natl Cancer Inst Monogr* 46:171-8, 1977.
30. Griffin TW, Rasey JS, **Bleyer WA**. The effect of photon irradiation on blood-brain barrier permeability to methotrexate in mice. *Cancer* 40:1109-11, 1977.
31. **Bleyer WA**. Clinical pharmacology of intrathecal methotrexate. 2. An improved dosage regimen derived from age-related pharmacokinetics. *Cancer Treat Rep* 61:1419-25, 1977.
32. Hammond GD, **Bleyer WA**, Hartmann JR, Hays DM, Jenkin RDT. Perspectives in pediatric oncology. *Cancer* 41:29-35, 1978.
33. **Bleyer WA**. The clinical pharmacology of methotrexate. New applications of an old drug. *Cancer* 41:36-51, 1978.
34. **Bleyer WA**, Poplack DG, Simon RM. "Concentration x time" methotrexate via a subcutaneous reservoir: A less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. *Blood* 51:835-42, 1978.
35. Oliff A, **Bleyer WA**, Poplack DG. Acute encephalopathy after initiation of cranial irradiation for meningeal leukemia. *Lancet* 2:1315, 1978.
36. Ahmad S, Shen F., **Bleyer WA**. Methotrexate-induced renal failure and ineffectiveness of peritoneal dialysis. *Arch Intern Med* 138:1146-7, 1978.
37. Ablin AR, **Bleyer WA**, Finklestein JA, Hartmann JR, Leikin S, Hammond GD. Failure of moderate-dose prolonged-infusion methotrexate and citrovorum factor rescue in patients with previously treated metastatic neuroblastoma - a phase II study. *Cancer Treat Rep* 62:1097-9, 1978.
38. **Bleyer WA**, Pizzo PA, Spence AM, Platt WD, Benjamin DR, Kolins J, Poplack DG. The Ommaya reservoir: Newly recognized complications and recommendations for insertion and use. *Cancer* 41:2431-7, 1978.
39. Wendling LR, **Bleyer WA**, DiChiro G, McIlvanie SK. Transient severe periventricular hypodensity after leukemia prophylaxis with cranial irradiation and intrathecal methotrexate. *J Comput Assist Tomogr* 2:502-5, 1978.
40. Pizzo PA, Poplack DG, **Bleyer WA**. Neurotoxicities of current leukemia therapy. *Am J Pediatr Hematol Oncol* 1:127-40, 1979.

41. **Bleyer WA**, Koup JR. Medication errors during intensive care. *Am J Dis Child* 133:366-7, 1979.
42. Poplack DG, **Bleyer WA**, Pizzo PA. Experimental approaches to the treatment of central-nervous-system leukemia. *Am J Pediatr Hematol Oncol* 1:141-9, 1979.
43. **Bleyer WA**, Krivit W, Chard RL, Hammond D. A phase 11 study of VM-26 in acute leukemia, neuroblastoma and other refractory childhood malignancies. A Report from the Childrens Cancer Study Group. *Cancer Treat Rep* 63:977-81, 1979.
44. **Bleyer WA**, Poplack DG. Intraventricular versus intralumbar methotrexate for central-nervous-system leukemia. *Med Pediatr Oncol* 6:207-13, 1979.
45. Oliff A, **Bleyer WA**, Poplack DG.. Methotrexate-induced oral mucositis and salivary methotrexate concentrations. *Cancer Chemother Pharmacol* 2:225-6, 1979.
46. Chard RL Jr, Krivit W, **Bleyer WA**, Hammond D. Phase 11 study of VP-l6-213 in childhood malignant disease: A Childrens Cancer Study Group report. *Cancer Treat Rep* 63:1755-9, 1979.
47. Gangji D, Reaman GH, Cohen SE, **Bleyer WA**, Poplack DG. Leukoencephalopathy and elevated levels of myelin basic protein in the cerebrospinal fluid of patients with acute lymphoblastic leukemia. *N Engl J Med* 303:19-21, 1980.
48. Bode U, Magrath IT, **Bleyer WA**, Poplack DG, Glaubiger DL. Active transport of methotrexate from cerebrospinal fluid in humans. *Cancer Res* 40:2184-7, 1980.
49. Gross S, Siegel S, **Bleyer A**, Coccia P, Hammond D. A toxicity study of cyclophosphamide induction therapy in childhood acute lymphocytic leukemia. *Am J Pediatr Hematol Oncol* 2:321-5, 1980.
50. Miser J, Miser A, Pendergrass TW, Reynolds F, Johnson FL, **Bleyer WA**, Bernstein ID, Hartmann JR, Chard RL. Seventy percent survival in childhood non-Hodgkin's lymphoma: Report of 21 cases treated with a less toxic LSA2-L2 regimen. *Am J Pediatr Hematol Oncol* 2:317, 1980.
51. Addiego JE, Ridgway D, **Bleyer WA**. The acute management of intrathecal methotrexate overdose: Pharmacologic rationale and guidelines. *J Pediatr* 98:825-8, 1981.
52. **Bleyer WA**. Cancer chemotherapy: Multimodal prospects for the 1980s. *Medicine* 8:3-9, 1981.
53. Izutsu KT, Truelove EL, **Bleyer WA**, Anderson WM, Schubert MM, Rice JC. Whole-saliva albumin as an indicator of stomatitis in cancer therapy patients. *Cancer* 48:1450-4, 1981.
54. **Bleyer WA**. Neurologic sequelae of methotrexate and ionizing radiation. A new classification. *Cancer Treat Rep* 65(Suppl 1):89-98, 1981.
55. Miser JS, Miser AW, **Bleyer WA**, Chard RL. Septicemia in childhood malignancy: Analysis of 101 consecutive cases. *Clinical Pediatr* 20:320-3, 1981.
56. Evans A, **Bleyer A**, Kaplan, Meadows AJ, Poplack DG, Sheline G. Central nervous system workshop. *Cancer Clin Trials* 4(Suppl):31-33, 1981.
57. **Bleyer WA**. Long-term adverse interactions between intrathecal and intravenous methotrexate and CNS irradiation. *Cancer Clinical Trials* 4(Suppl):33-34, 1981.
58. **Bleyer WA**. Delayed toxicities of chemotherapy on childhood tissues - 1981 update. *Frontiers Radiat Therap Oncol* 16:50-4, 1982.
59. Steinberg SE, Campbell CL, **Bleyer WA**, Hillman RS. The enterohepatic circulation of methotrexate. *Cancer Res* 42:1279-82, 1982.
60. Dinndorf PA, Clark BS, **Bleyer WA**. Bone marrow aspirations with a 22-gauge spinal needle. *J Pediatr* 100:595-6, 1982.
61. Riccardi R, Vigersky RA, Barnes S, **Bleyer WA**, Poplack DG. Methotrexate levels in the interstitial space and seminiferous tubules of rat testis. *Cancer Res* 42:1617-9, 1982.
62. **Bleyer WA**, Haas JE, Feigl P, Greenlee TK, Schaller RT Jr, Morgan A, Pendergrass TW, Johnson FL, Bernstein ID, Chard RL, Hartmann JR. Improved 3-year disease-free survival in osteogenic sarcoma. Efficacy of adjuvant chemotherapy. *J Bone Joint Surgery* 64-B:233-8, 1982.
63. Schaller RT, Haas J, Schaller J, Morgan A, **Bleyer WA**. Improved survival in children with osteosarcoma following resection of pulmonary metastases. *J Pediatr Surgery* 17:546-50, 1982.

64. Lampkin B, Woods W, Strauss R, Feig S, Higgins G, Bernstein I, D'Angio G, Chard R, **Bleyer A**, Hammond D. Current status of the biology and treatment of acute non-lymphocytic leukemia in children. Report from the Children's Cancer Study Group. *Blood* 61:215-28, 1983.
65. Balis FM, Savitch JL, **Bleyer WA**. Pharmacokinetics of oral methotrexate in children. *Cancer Res* 43:2342-5, 1983.
66. **Bleyer WA**. Acute lymphoid leukemia. *Pediatr Ann* 2:277-92, 1983.
67. Balis FM, Holcenberg JS, **Bleyer WA**. Clinical pharmacokinetics of commonly used anticancer drugs. *Clin Pharmacokinetics* 8:202-32, 1983.
68. **Bleyer WA**, Coccia PF, Sather HN, Level C, Lukens J, Niebrugge DJ, Siegel S, Littman PS, Leikin SL, Miller DR, Chard RL Jr, Hammond GD. Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. *J Clin Oncol* 1:317-25, 1983.
69. **Bleyer WA**. High-dose methotrexate therapy. *Clin Pharmacol (Am Soc Clin Path)* 4:1-10, 1983.
70. Gangji D, Ross WE, **Bleyer WA**, Poplack DG, Glaubiger DL. Probenecid inhibition of methotrexate cytotoxicity in mouse L1210 leukemia cells. *Cancer Treat Rep* 68:521-5, 1984.
71. **Bleyer WA**. Intrathecal methotrexate versus central nervous system leukemia. *Cancer Drug Delivery* 1:157-67, 1984.
72. Morgan E, Baum E, **Bleyer WA**, Movassaghi N, Provisor A, Lampkin B, Lukens J, Griffin T, White H, Fryer C, Hammond D. Treatment of patients with metastatic osteogenic sarcoma: A report from the Childrens Cancer Study Group. *Cancer Treat Rep* 68:661-4, 1984.
73. Rogers PCJ, **Bleyer WA**, Coccia P, Lukens JH, Siegel S, Sather H, Hammond D. Yield of unpredicted bone-marrow relapse diagnosed by routine bone marrow aspiration in children with acute lymphoblastic leukaemia. *Lancet* 1:1320-2, 1984.
74. Morse ME, Savitch JL, **Bleyer WA**. Altered central-nervous-system pharmacology of methotrexate in childhood leukemia: Another sign of meningeal leukemia. *J Clin Oncol* 3:19-24, 1985.
75. Balis FM, Savitch JL, **Bleyer WA**, Reaman GH, Poplack DG. Remission induction of meningeal leukemia with high dose intravenous methotrexate. *J Clin Oncol* 3:485-9, 1985.
76. Miller DR, Krailo M, **Bleyer WA**, Lukens JN, Siegel SE, Coccia PR, Weiner J, Hammond D. Prognostic implications and concordance of FAB morphology in childhood acute lymphoblastic leukemia: A report from the Childrens Cancer Study Group. *Cancer Treat Symp* 69:1211-21, 1985.
77. **Bleyer WA**, Poplack DG. Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. *Semin Oncol* 12:131-48, 1985.
78. Reaman G, Zeltzer P, **Bleyer WA**, Amendola B, Level C, Sather H, Hammond D. Acute lymphoblastic leukemia in infants less than one year of age: A cumulative experience of the Childrens Cancer Study Group. *J Clin Oncol* 3:1513-21, 1985.
79. Blatt J, Sherins R, Niebrugge D, **Bleyer WA**, Poplack DG. Leydig cell function in boys following treatment for testicular relapse of acute lymphoblastic leukemia. *J Clin Oncol* 3:1227-31, 1985.
80. **Bleyer WA**. Cancer chemotherapy in infants and children. *Pediatr Clin North Am* 32:557-74, 1985.
81. Steinherz PG, Gaynon P, Miller DR, Reaman G, **Bleyer A**, Finklestein J, Evans RG, Meyers P, Steinherz L, Sather H, Hammond D. Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen - A new intensive therapy protocol. *J Clin Oncol* 4:744-52, 1986.
82. **Bleyer WA**, Sather H, Hammond GD. Prognosis and treatment after relapse of acute lymphoblastic leukemia and non-Hodgkin's lymphoma: 1985. A report from the Childrens Cancer Study Group. *Cancer* 58(Suppl):590-4, 1986.
83. Mastrangelo R, Poplack D, **Bleyer A**, Riccardi R, Sather H, D'Angio G. Report and recommendations of the Rome Workshop concerning poor-prognosis acute lymphoblastic leukemia in children: Biologic bases for staging, stratification and treatment. *Med Pediatr Oncol* 14:191-4, 1986.
84. Hammond D, Sather H, Nesbit M, Miller D, Coccia P, **Bleyer A**, Lukens J, Siegel S. Analysis of prognostic factors in acute lymphoblastic leukemia. *Med Pediatr Oncol* 14:124-34, 1986.

85. **Bleyer WA**, Sather HA, Coccia P, Lukens J, Siegel S, Hammond GD. The staging of childhood acute lymphoblastic leukemia. Strategies of the Childrens Cancer Study Group and a three-dimensional technic of multivariate analysis. *Med Pediatr Oncol* 15:271-280, 1986.
86. Littman PS, Coccia PF, **Bleyer WA**, Lukens JN, Siegel SE, Miller DR, Sather HN, Hammond GD. Central nervous system prophylaxis in children with low risk acute lymphoblastic leukemia. *Int J Radiat Oncol Biol Phys* 13:1443-9, 1987.
87. Pendergrass TW, Geyer RJ, Milstein JM, Mulne AF, Stuntz JT, Kosnik EJ, Morris JD, Heideman RL, Ruymann FB, **Bleyer WA**. Eight drugs in one day chemotherapy for brain tumors: Experience in 107 children and rationale for preradiation chemotherapy. *J Clin Oncol* 5:1221-31, 1987.
88. Hammond GD, Sather H, **Bleyer WA**, Coccia P. Stratification by prognostic factors in the design and analysis of clinical trials for acute lymphoblastic leukemia. *Haematol Blood Transfusion* 30:161-66, 1987.
89. Gaynon PS, Steinherz GH, Reaman GH, **Bleyer WA**, Sather H, Hammond GD. Strategies for the treatment of children with acute lymphoblastic leukemia and unfavorable presenting features. *Haematol Blood Transfusion* 30:167-172, 1987.
90. Krailo M, Ertel I, Makley J, Fryer CJ, Baum E, Weetman R, Yunis E, Barnes L, **Bleyer WA**, Hammond GD. A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components of adjuvant chemotherapy in childhood nonmetastatic osteosarcoma: a report from the Childrens Cancer Study Group. *Med Pediatr Oncol* 15(2):69-77, 1987.
91. Browne MJ, Dinndorf PA, Perek D, Commers J, **Bleyer WA**, Poplack DG, Pizzo PA. Infectious complications of intraventricular reservoirs in cancer patients. *Pediatr Inf Dis J* 6:182-9, 1987.
92. Dinndorf PA, **Bleyer WA**. Management of infectious complications of intraventricular reservoirs in cancer patients: Low incidence and successful treatment without reservoir removal. *Cancer Drug Delivery* 4:105-117, 1987.
93. Webber BL, Tanyer G, Poplack D, Reaman G, Feusner J, Miser J, **Bleyer A**. Transient acute hepatotoxicity of high-dose methotrexate [33.6 mg²] therapy during childhood. *NCI Monographs* 5:207-212, 1987.
94. Streissguth AP, Treder RP, Barr HM, Shepard TH, **Bleyer WA**, Sampson PD, Martin DC. Aspirin and acetaminophen use by pregnant women and subsequent child IQ and attention decrements. *Teratology* 35:211-219, 1987.
95. Reaman GH, Steinherz PG, Gaynon PS, **Bleyer WA**, Finklestein JZ, Evans R, Miller DR, Sather HS, Hammond GD. Improved survival of infants less than 1 year of age with acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. *Cancer Treat Rep* 71:1033-8, 1987.
96. Murphy SB, **Bleyer WA**. Cranial irradiation is not necessary for central-nervous-system prophylaxis in pediatric non-Hodgkin's lymphoma. *Int J Radiat Oncol Biol Phys* 13:467-8, 1987.
97. Makley JT, Krailo M, Ertel IJ, Fryer CJH, Baum ES, Weetman RM, Yunis EJ, **Bleyer WA**, Hammond GD. The relationship of various aspects of surgical management to outcome in childhood nonmetastatic osteosarcoma: A report from the Childrens Cancer Study Group. *J Pediatr Surg* 23:146-51, 1988.
98. Taylor EM, Geyer JR, Milstein JM, Shaw CM, Geraci JP, Wootton P, Hubbard BA, **Bleyer WA**. A rodent model of chemoradiotherapy-induced white matter necrosis. *NCI Mongr* 6:59-64, 1988.
99. Geyer JR, Taylor EM, Milstein JM, Shaw CM, Hubbard BA, Geraci JP, **Bleyer WA**. Radiation, methotrexate and white matter necrosis. Laboratory evidence for neural radioprotection with pre-radiation methotrexate. *Int J Radiat Oncol Biol Phys* 15:373-375, 1988.
100. Gaynon PS, **Bleyer WA**, Steinherz PG, Finklestein JZ, Littman PS, Miller DR, Reaman GH, Sather HN, Hammond GD. Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. A report from the Childrens Cancer Study Group. *Am J Ped Hematol Oncol* 10:42-50, 1988.
101. Geyer JR, Pendergrass TW, Milstein JM, **Bleyer WA**. Eight drugs in one day chemotherapy in children with brain tumors: A critical toxicity appraisal. *J Clin Oncol* 6:996-1000, 1988.
102. Maurer MS, Steinherz PG, Gaynon PG, Finklestein JZ, Sather HN, Reaman GH, **Bleyer WA**, Hammond GD. The effect of initial management of hyperleukocytosis on early complications and outcome of children with acute lymphoblastic leukemia. *J Clin Oncol* 6:1425-32, 1988.

103. Gaynon PS, Steinherz PG, **Bleyer WA**, Ablin AR, Albo VC, Finklestein JZ, Grossman NJ, Littman PS, Novak LT, Pyesmany AF, Reaman GH, Sather HN, Hammond GD. Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features. *Lancet* 2:921-4, 1988.
104. **Bleyer WA**. Central nervous system leukemia. *Pediatr Clinics No Am* 35:789-814, 1988.
105. **Bleyer WA**. Hobson's choice in CNS radioprophylaxis of small cell lung cancer. *Int J Radiat Oncol Biol Phys* 15:783-5, 1988.
106. Wallace CA, **Bleyer WA**, Sherry DD, Salmonson KL, Wedgwood RJ. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. *Arthritis Rheumatism* 32:677-81, 1989.
107. **Bleyer WA**. New vistas for leucovorin in cancer chemotherapy. *Cancer* 63:995-1007, 1989.
108. **Bleyer WA**. Biology and pathogenesis of CNS leukemia. *Am J Ped Hematol Oncol* 11:57-63, 1989.
109. Ridgway D, Neerhout RC, **Bleyer A**. Attenuation of asparaginase-induced hyperglycemia after substitution of the *Erwinia carotovora* for the *Escherichia coli* enzyme preparation. *Cancer* 63:561-3, 1989.
110. **Bleyer WA**. Remaining problems in the staging and treatment of childhood acute lymphoblastic leukemia. *Am J Ped Hematol Oncol* 11:371-9, 1989.
111. Miller DR, Coccia PF, **Bleyer WA**, Lukens JN, Siegel SE, Sather HN, Hammond GD. Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: A report from the Childrens Cancer Study Group. *J Clin Oncol* 7:1807-15, 1989.
112. Milstein JM, Geyer JR, Berger MS, **Bleyer WA**. Favorable prognosis for brainstem gliomas in neurofibromatosis. *J Neuro-Oncol* 7:367-71, 1989.
113. Kowal-Vern A, Almanaseer I, **Bleyer A**. Intracranial lymphoblastic sarcoma mimicking a primary brain tumor. *Pediatr Neurosci* 15:136-8, 1989.
114. **Bleyer WA**, Hunt DD, Carline JD, Trevisan M, Johnson S, Phillips TJ. Improvement of oncology education at the University of Washington, 1984-1988. *Acad Med* 65:114-9, 1990.
115. Nachman J, Palmer NF, Sather HN, **Bleyer WA**, Coccia PF, Lukens JN, Siegel SE, Hammond GD. Open-wedge testicular biopsy in childhood acute lymphoblastic leukemia after two years of maintenance therapy: Diagnostic accuracy and influence on outcome - A report from the Childrens Cancer Study Group. *Blood* 75:1051-5, 1990.
116. Gaynon PS, **Bleyer WA**, Steinherz PG, Finklestein JZ, Littman P, Miller DR, Reaman G, Sather H, Hammond GD. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. *Med Pediatr Oncol* 18:273-9, 1990.
117. Adamson PC, Balis FM, Miser J, Wells RJ, **Bleyer WA**, Williams TE, Gillespie A, Penta JS, Clendeninn NJ, Poplack DG. Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a 5-day schedule. *Cancer Res* 50:4464-7, 1990.
118. **Bleyer WA**. The impact of childhood cancer on the United States and the World. *CA Cancer J Clin* 40:355-67, 1990
119. **Bleyer WA**, Fallavollita J, Robison L, Balsom W, Meadows A, Heyn R, Sitarz A, Ortega J, Miller D, Constine L, Nesbit M, Sather H, Hammond D. Influence of age, sex and concurrent intrathecal methotrexate therapy on intellectual function after cranial irradiation during childhood: A report from the Childrens Cancer Study Group. *Pediatr Hematol Oncol* 7:329-38, 1990.
120. **Bleyer WA**. Acute lymphoblastic leukemia in children. Advances and prospectus. *Cancer* 65:689-95, 1990.
121. Balch CM, **Bleyer WA**, Krakoff IH, Peters LJ. The vital role of animal research in advancing cancer diagnosis and treatment. *The Cancer Bulletin* 42:266-9, 1990.
122. Allen J, Packer R, **Bleyer A**, Zeltzer P, Prados M, Nirenberg A. Recombinant interferon beta: A phase I-II trial in children with recurrent brain tumors. *J Clin Oncol* 9:783-8, 1991.
123. Geyer JR, Taylor EM, Milstein JM, Shaw CM, Hubbard BA, Geraci JP, **Bleyer WA**. The effect of age on the latency of radiation myelopathy. *J Neuro-Oncol* 10:145-51, 1991.
124. **Bleyer WA**, Sather HN, Nickerson HJ, Coccia PF, Finklestein JZ, Miller DR, Littman PS, Lukens JN, Siegel SE, Hammond GD. Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia. A Report of the CCG-161 Study by the Childrens Cancer Study Group. *J Clin Oncol* 9:1012-21, 1991.

125. Gaynon PS, Steinherz PG, **Bleyer WA**, Finklestein JZ, Miller DR, Reaman GR, Sather HN, Hammond GD. Association of delivered drug dose and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. *Med Pediatr Oncol* 19:221-7, 1991.
126. Steinherz PG, Siegel SE, **Bleyer WA**, Kersey J, Chard R, Coccia P, Leikin S, Lukens J, Neerhout R, Nesbit M, Miller DR, Reaman G, Sather H, Hammond D. Lymphomatous presentation of childhood acute lymphoblastic leukemia. A subgroup at high risk of early treatment failure. *Cancer* 68:751-8, 1991.
127. Geyer R, Levy M, Berger MS, Milstein J, Griffin B, **Bleyer WA**. Infants with medulloblastoma: A single institution review of survival. *Neurosurg* 29:707-11, 1991.
128. Balsom WR, **Bleyer WA**, Robison LL, Heyn RM, Meadows AT, Sitarz A, Blatt J, Sather HN, Hammond GD. Intellectual function in long-term survivors of childhood acute lymphoblastic leukemia: Protective effect of pre-irradiation methotrexate? A Childrens Cancer Group Study. *Med Pediatr Oncol* 19:486-92, 1991.
129. **Bleyer WA**. Pediatric oncology. *The Cancer Bulletin* 44:439-40, 1992.
130. **Bleyer WA**. Magnitude of the childhood cancer problem. *The Cancer Bulletin* 44:444-50, 1992.
131. **Bleyer WA**. Principles of cancer chemotherapy in children. *The Cancer Bulletin* 44:461-9, 1992.
132. Feig SA, Krailo MD, Harris RE, Baum E, Holcenberg J, Kaizer H, Steinherz L, Pendergrass TW, Saunders EF, Warkentin PL, **Bleyer WA**, Hammond GD. Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin. *Med Pediatr Oncol* 20:124-9, 1992.
133. Hammond GD, Haase GM, Krawiec V, **Bleyer WA**, Severson RK, Bernstein L, Krisher JP, Smith MS, Brady AM, Menck H. Patterns of Care. *Cancer* 71:3202-5, 1993.
134. **Bleyer WA**. What can be learned about childhood cancer from "Cancer Statistics Review 1973-1988." *Cancer* 71:3229-36, 1993.
135. Gaynon PS, Steinherz PG, **Bleyer WA**, Ablin AR, Albo VC, Finklestein JZ, Grossman NJ, Novak LJ, Pyesmany AF, Reaman GH, Chappell RJ, Sather HN, Hammond GD. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: A follow-up report of the Childrens Cancer Group Study CCG-106. *J Clin Oncol* 11:2234-2242, 1993.
136. **Bleyer WA**, Smith RA, Green DM, et al. Workshop #1: Long term survivors of childhood cancer. *Cancer* 71:2143, 1993.
137. Geyer JR, Zeltzer PM, Boyett JM, Rorke LB, Stanley P, Albright AL, Wisoff JH, Milstein JM, Allen JC, Finlay JL, Ayers GD, Shurin SB, Stevens KR, **Bleyer WA**. Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: A report from the Childrens Cancer Group. *J Clin Oncol* 12:1607-15, 1994.
138. Desch MD, **Bleyer WA**. Amended long-term trends in cancer incidence in children. *J Natl Cancer Inst* 86:1481-2, 1994.
139. **Bleyer WA**, Tubergen DG. Central nervous system relapse in children with acute lymphoblastic leukemia. *Int J Radiat Oncol Biol Phys* 31:673-4, 1995.
140. **Bleyer WA**. The past and future of cancer in the young. *Pediatr Dentistry* 17:285-90, 1995.
141. Przepiorcka D, Chan K-W, Champlin RE, Culbert SJ, Petropoulos D, Ippoliti C, Khouri I, Huh YO, Vreisendorp H, Deisseroth AB, **Bleyer WA**. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients. *Bone Marrow Transplant* 16:737-41, 1995.
142. Sievers EL, Smith FO, Lee JW, Woods WG, **Bleyer WA**, Bernstein ID. Cell surface expression of the multidrug resistance p-glycoprotein (p-170) as detected by monoclonal antibody MRK16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: A report from the Children's Cancer Group. *Leukemia* 9:2042-8, 1995.
143. **Bleyer WA**. Leukoencephalopathy detectable by magnetic resonance imaging: Much ado about nothing? *Int J Radiat Oncol Biol Phys* 32:1251-2, 1995.
144. Berg JH, **Bleyer WA**. Pediatric dentistry in care of the cancer patient. *Pediatr Dentistry* 17:257-8, 1995.
145. **Bleyer A**. CNS chemoradiotherapy of childhood leukemia: The plot thickens but the ending bodes well. *J Clin Oncol* 13:2480-1, 1995.

146. Steinherz P, Gaynon P, Breneman JC, Cherlow J, Grossman NJ, Kersey JH, Johnstone HS, Sather HN, Trigg ME, Chappell R, Hammond D, **Bleyer WA**. Cytoreduction and prognosis in acute lymphoblastic leukemia—The importance of early marrow response: Report from the Childrens Cancer Group. *J Clin Oncol* 14:389-98, 1996.
147. Chan KW, Gajewski JL, Supkis D, Pentz R, Champlin R, **Bleyer WA**. The use of minors as bone marrow donors: Current attitude and management. A survey of 54 pediatric transplant centers. *J Pediatr* 128:644-8, 1996.
148. Jardine LF, Ingram LC, **Bleyer WA**. Intrathecal leucovorin after intrathecal methotrexate overdose. *J Pediatric Hematol/Oncol* 18:302-304, 1996.
149. Geyer JR, Balis FM, Krailo MD, Heideman R, Broxon E, Sato JK, Poplack D, **Bleyer WA**. A phase I study of thioTEPA in children with recurrent solid tumor malignancies: A Children's Cancer Group study. *Invest New Drug* 13:337-342, 1996.
150. **Bleyer WA**. The adolescent gap in cancer treatment. *J Registry Management* 23:114-5, 1996.
151. Weiss NS, Katz JA, Frankel LS, Lloyd LE, McClain K, Walker LR, Torges K, Thomas PJ, **Bleyer WA**. Incidence of childhood and adolescent cancer in Texas. *Texas Medicine* 92:54-60, July 1996.
152. Cherlow JM, Sather H, Steinherz P, Gaynon P, Tubergen D, Trigg M, Novak L, **Bleyer WA**. Craniospinal irradiation for acute lymphoblastic leukemia with CNS disease at diagnosis - A report from the Childrens Cancer Group. *Int J Radiat Oncol Biol Phys* 36:19-27, 1996.
153. Feig SA, Ames MM, Sather HN, Steinherz L, Reid JM, Trigg M, Pendergrass TW, Warkentin P, Gerber M, Leonard M, **Bleyer WA**, Harris RE. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: A report from Children's Cancer Group. *Med Pediatr Oncol* 27:505-14, 1996.
154. Alberts DS, **Bleyer WA**. Future development of amifostine in cancer treatment. *Semin Oncol* 23:90-99, 1996.
155. Masera G, Pession A, Rondelli R, Valsecchi MG, Reiter A, Riehm H, Schrappe M, McIntyre OR, **Bleyer WA**, Cairo M, Gaynon P, Reaman G, Sather H, Trigg M, Auclerc M-F, Bancillon A, Lepage E, Schaison G, Clavell L, Dutton V, Donnelly M, Gelber R, Sallan SE, Sackman-Murial F, Santarelli MT, Perez C, Soidoro A, Bailey C, Burnett A, Chessels J, Eden OB, Gordon-Smith EC, Lilleyman J, Land VJ, Mahoney D, Murphy S, Steuber CP, Vietti T, Crist W, Hancock M, Pui C-H, Simone J, Mittra I. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukemia: 42 trials involving 12,000 randomized children. *Lancet* 347:1783-8, 1996.
156. Clark BS, Gallegos E, **Bleyer WA**. Accidental intramuscular vincristine: lack of untoward effects and recommendations for management. *Med Pediatr Oncol* 28:314-5, 1997.
157. Furman WL, Luo X, Fairclough D, Garrison L, Marina N, Pratt CB, **Bleyer A**, Meyer MH. Phase I trial of subcutaneous interleukin-1 in children with malignant disease. *Med Pediatr Oncol* 29:444-450, 1997.
158. Hardy RD, Duvic M, **Bleyer WA**. The sign of Leser-Trelat. *Med Pediatr Oncol* 28:234-7, 1997.
159. **Bleyer WA**. The U.S. pediatric cancer clinical trials programmes: International implications and the way forward. *European J Ca* 33:1439-47, 1997.
160. Gurney JG, Ross JA, Wall DA, **Bleyer WA**, Severson RK, Robison LL. Infant cancer in the U.S.: Histology-specific incidence and trends, 1973-1992. *J Pediat Hemat Oncol* 19:428-32, 1997.
161. **Bleyer WA**, Tejada H, Murphy SM, Brawley OW, Smith MA, Ungerleider RS. Equal participation of minority patients in U.S. national pediatric cancer clinical trials. *J Pediat Hemat/Oncol* 19:423-7, 1997.
162. **Bleyer WA**, Tejada H, Murphy SM, Robison LL, Ross JA, Pollock BH, Severson RK, Brawley OW, Smith MA, Ungerleider RS. National cancer clinical trials: children have equal access; adolescents do not. *J Adol Health* 21:366-73, 1997.
163. **Bleyer WA**, Nelson JA, Kamen BA. Accumulation of methotrexate in systemic tissues after intrathecal administration. *J Ped Hemat Oncol* 19:530-2, 1997.
164. **Bleyer WA**. Methotrexate induced lymphoma? [editorial] *J Rheumatol* 25(3):404-7 1998.
165. Smith MS, Bernstein M, **Bleyer WA**, Borsi J, Ho P, Lewis IJ, Pearson A, Pein F, Pratt C, Reaman G, Riccardi R, Seibel N, Trueworthy R, Ungerleider R, Vassal F, Vietti T. The conduct of phase I trials in children with cancer: *J Clin Oncol* 16:966-78, 1998.
166. **Bleyer WA**, Fujimoto T, Nakazawa S. Second United States – Japan Symposium on Pediatric Cancer. *International J Pediat Hemat/Oncol* 5:43-68, 1998.

167. Ater JL, Gardner KL, Foxhall LE, Therrell BL, **Bleyer WA**. Neuroblastoma screening in the United States. Results of the Texas Outreach Program for neuroblastoma screening. *Cancer* 82:1593-603, 1998.
168. **Bleyer WA**. Chemoradiotherapy interactions in the central nervous system. *Med Pediatr Oncol* Suppl 1,10-16, 1998.
169. Balis RM, Holcenberg JS, Poplack DG, Ge J, Sather HN, Murphy RF, Ames MM, Waskerwitz MJ, Tubergen DG, Zimm S, Gilchrist GS, **Bleyer WA**. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: A joint Children's Cancer Group and Pediatric Branch study. *Blood* 92:3569-77, 1998.
170. Blaney SM, Needle MN, Gillepsie A, Sato JK, Reamsn GH, Berg SI, Adamson PC, Krailo MD, **Bleyer WA**, Poplack DG, Balis FM. Phase II trial of topotecan administered as a 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. *Clin Cancer Res* 4:357-60, 1998.
171. Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, Johnstone HS, Sather HN, Trigg ME, Uckun FM, **Bleyer WA**. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor-prognosis features: Randomized controlled trial from the Children's Cancer Group. *Cancer* 82:600-12, 1998.
172. **Bleyer WA**. Epidemiologic impact of children with brain tumors. *Child's Nerv Syst* 15:758-63, 1999.
173. **Bleyer WA**. Intrathecal depot cytarabine therapy: A welcome addition to a limited armamentarium. *Clin Cancer Res* 5:5349-51, 1999.
174. **Bleyer WA**, Danielson MG. Oral cancer chemotherapy in paediatric patients. *Drugs* 58: suppl 3;133-40, 1999.
175. Gaynon PS, Trigg ME, Heerema H, Sensel MG, Sather H, Hammond GD, **Bleyer WA**. Children's Cancer Group trials in acute lymphoblastic leukemia: 1983-1995. *Leukemia* 14:2223-33, 2000.
176. **Bleyer WA**. United States pediatric cancer mortality—an ominous trend? *Med Pediatr Oncol* 36:337-9, 2001.
177. Doolittle ND, Anderson CP, **Bleyer WA**, Cairncross JG, Cloughesy T, Eck SL, Guastadisegni P, Hall WA, Muldoon LL, Patel SJ, Peereboom D, Siegal T, Neuwelt EA. Importance of dose intensity in neuro-oncology clinical trials. *Neuro-Oncol* 3:46-54, 2001.
178. Agarwal B, **Bleyer A**, Cutland S, Hesselning P. Pediatric oncology in developing countries: Development of an alliance of stakeholders. *Med Pediatr Oncol* 36:305-9, 2001.
179. Murray JC, Grier H, **Bleyer WA**, Anderson B. Moving more adolescents, young adults into cancer trials. *CAP Today (College of American Pathologists)* 15(6): 11-12, 2001.
180. **Bleyer WA**. Overview: Cancer in adolescents and young adults: Epidemiology, diagnosis, treatment, survival, and importance of clinical trials. *Med Pediatr Oncol* 38:1-10, 2002.
181. Okcu F, Goodman K, Carozza S, Burau K, **Bleyer A**, Cooper S. Birth weight, ethnicity and occurrence of cancer in children: a population-based, incident, case-control study in the State of Texas. *Ca Causes Control* 13:595-602, 2002.
182. Sarris AH, Phan A, Goy A, Romaguera J, Hagemester FB, Rodriguez MA, McLaughlin P, Pro B, Medeiros LJ, Samuels B, Mesina O, **Bleyer AW**, Cabanillas F. Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial. *Oncology* 16(8 Suppl 7):27-31, 2002.
183. **Bleyer A**. Older adolescents with cancer in North America: Deficits in outcome and research. *Pediatr Clin N Amer* 49:1027-42, 2002.
184. Searle NS, Askins M, **Bleyer WA**. Homebound schooling is the least favorable option for continued education of adolescent cancer patients: A preliminary report. *Med Pediatr Oncol* 40:380-384, 2003.
185. Albritton K, **Bleyer A**. The management of cancer in the older adolescent. *Europ J Ca* <http://authors.elsevier.com/sd/article/S0959804903008098>, 39:2548-99, 2003.
186. Oki Y, McLaughlin P, Pro B, Hagemester FB, **Bleyer A**, Loyer E, Younes A. Oxaliplatin in patients with relapsed or refractory non-Hodgkin's lymphoma. *J Clin Oncol* 104:781-7, 2005.
187. Doolittle ND, Abrey LE, **Bleyer WA**, Brem S, Davis TP, Dore-Duffy P, Drewes LR, Hall WA, Hoffman JR, Korfel A, Martuza R, Muldoon LL, Peereboom D, Peterson DR, Rabkin SD, Smith Q, Stevens GHJ, Neuwelt EA. New frontiers in translational research in neuro-oncology and the blood-brain barrier: Report of the Tenth Annual Blood-Brain Barrier Disruption Consortium Meeting. *Clin Cancer Res* 11:421-8, 2005.

188. **Bleyer A**, Montello M, Budd T, Saxman S. National survival trends of young adults with sarcoma: Lack of progress is associated with lack of clinical trial participation. *Cancer* 103(9):1891-7, 2005.
189. **Bleyer A**. The adolescent and young adult gap in cancer care and outcome. *Curr Probl Pediatr Adolesc Health Care*. 35(5):182-217, 2005.
190. **Bleyer A**, Budd T, Montello M. Lack of clinical trial participation and of progress in older adolescents and young adults with cancer. *Curr Probl Pediatr Adolesc Health Care* 35(5):186-95, 2005.
191. Kumar A, Soares H, Wells R, Clarke M, Hozo I, **Bleyer A**, Reaman G, Chalmers I, Djulbegovic B. Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group. *BMJ* 331:1295-301, 2005.
192. Johansen M, Kuttesch JF, **Bleyer WA**, Krailo MD, Ames MM, Madden T. Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group. *Clin Cancer Res* 12(2):516-22, 2006.
193. **Bleyer A**, Barr R. Cancer in 15- to 29-year-olds by primary site. *Oncologist* 11(7):590-601, 2006.
194. Nathan PC, Whitcomb T, Wolters PL, Steinberg SM, Balis FM, Brouwers P, Hunsberger S, Feusner J, Sather H, Miser J, Odom LF, Poplack D, Reaman G, **Bleyer WA**. Very high-dose methotrexate (33.6 g/m²) as CNS preventive therapy for childhood acute lymphoblastic leukemia: Results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P, and CCG-144P. *Leuk Lymph* 47(12):2488-504, 2006.
195. **Bleyer A**, Morgan S, Barr R. Supplement: Walking Two Worlds—Adolescent and Young Adult Oncology. Proceedings of a workshop: Bridging the gap in care and addressing participation in clinical trials. *Cancer* 107(S7):1645–55, 2006.
196. **Bleyer A**, Budd T, Montello M. Adolescents and young adults with cancer: The scope of the problem and criticality of clinical trials. *Cancer* 107(7 Suppl):1645-55, 2006.
197. Ajani JA, Jiang Y, Faust J, Chang BB, Yao JC, Craig C, **Bleyer A**. A multi-center phase II study of sequential bryostatins-1 (NSC 339555) and paclitaxel in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. *Invest New Drugs* 24:353-7, 2006.
198. Zebrack B, **Bleyer A**, Albritton K, Madearis S, Tang J. Assessing the health care needs of adolescent and young adult cancer patients and survivors. *Cancer* 107:2915-23, 2006.
199. Bleyer A. Epoetin versus darbepoetin conundrum compromise. *J Clin Oncol*. 24(25):e46, 2006 Sep. doi:10.1200/JCO.2006.07.5325. PMID: 16943519.
200. Ferrari A, **Bleyer A**. Participation of adolescents with cancer in clinical trials. *Cancer Treat Rev* 33:603-608, 2007.
201. Butturini AM, Dorey FJ, Gaynon PS, Fu C, Franklin J, Siegel S, Sacks N, Seibel N, Henry DW, Rogers PC, Lange B, Sather H, Trigg M, Carroll WL, **Bleyer WA**. Obesity and outcome in pediatric acute lymphoblastic leukemia. *J Clin Oncol* 25:2063-9, 2007.
202. **Bleyer A**. Adolescent and young adult (AYA) oncology: The first A. *Pediatr Hematol Oncol*, 24:325–36, 2007.
203. **Bleyer A**. Young adult oncology: The patients and their survival challenges. *CA Cancer J Clin* 57(4):242-55, 2007.
204. Martin S, Ulrich C, Munsell M, Taylor S, Lange G, **Bleyer A**. Delays in cancer diagnosis in under-insured young adults and older adolescents. *The Oncologist* 12(7):816-24, 2007.
205. Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Matin S, Kamat A, Pisters LL, Lin D, Katz RL, Brenner DE, Hemstreet GP, Wargo MW, **Bleyer A**, Sanders WH, Clifford JL, Parnes HL, Lippman SM. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. *Clin Cancer Res* 14:224-9, 2008.
206. **Bleyer A**, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B. The distinctive biology of cancer in adolescents and young adults. *Nature Reviews Cancer* 8(4):288-98, 2008.
207. Ferrari A, Montello M, Budd T, **Bleyer A**. The challenges of clinical trial participation for adolescents and young adults with cancer. *Pediatr Blood Ca* 50(5):1101-4, 2008.
208. **Bleyer A**. Returning to work after parenting a child with the most curable chronic disease. *Pediatr Blood Ca* 51:1 2, 2008.
209. **Bleyer A**, Barr R. Cancer in young adults 20- to 39-years of age: Overview. *Semin Oncol* 36(3):193-205, 2009.

210. **Bleyer A.** CAUTION: Consider cancer: Common symptoms and signs for early detection of cancer in young adults. *Semin Oncol* 36(3):206-12, 2009.
211. Anders C, Johnson R, Litton J, Phillips M, **Bleyer A.** Breast cancer before age 40 years. *Semin Oncol* 36(3):230-42, 2009.
212. Kuttesch JF, Krailo MD, Madden T, Johansen M, **Bleyer A.** Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: A Children's Oncology Group study. *Pediatr Blood Ca* 53(4):590-3, 2009.
213. **Bleyer A,** Choi M, Wang SJ, Fuller CD, Raney RB. Increased vulnerability of the spinal cord to radiation and intrathecal chemotherapy during adolescence: A report from the Children's Oncology Group. *Pediatr Blood Ca* 53(7):1205-10, 2009.
214. **Bleyer A.** The quid pro quo of pediatric versus adult services for older adolescent cancer patients. *Pediatr Blood Ca* 54(2): 238-41, 2009.
215. **Bleyer A,** Choi M, Fuller CD, Thomas CR, Wang SJ. Relative lack of conditional survival improvement in adolescents and young adults with cancer. *Semin Oncol* 36(5):460-7, 2009.
216. **Bleyer A,** Barr R. Introduction—Impact of malignant diseases on young adults II. *Semin Oncol* 36(5):380, 2009.
217. Zbuk K, Sidebotham EL, **Bleyer A,** La Quaglia MP. Colorectal cancer in young adults. *Semin Oncol* 36(5):439-50, 2009.
218. **Bleyer A.** Cancer of the oral cavity and pharynx in young females: Increasing incidence, role of human papilloma virus, and lack of survival improvement. *Semin Oncol* 36(5):451-9, 2009.
219. Albritton A, Barr R, **Bleyer A.** The adolescence of young adult oncology. *Semin Oncol* 36(5):478-88, 2009.
220. Stork LC, Matloub Y, Broxson E, La M, Yanofsky R, Sather H, Hutchison R, Heerema NA, Sorrell AD, Masterson M, **Bleyer A,** Gaynon PS. Oral 6-mercaptopurine vs. oral 6-thioguanine and veno-occlusive disease in children with standard risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial. *Blood* 115(14):2740-8, 2010.
221. Vriens MR, Moses W, Weng J, Pengl M, Ruan D, Suh I, Griffin A, **Bleyer A,** Pollock BH, Indelicato DJ, Hwang J, Kebebew E. Clinical and molecular features of papillary thyroid cancer in adolescents and young adults. *Cancer* 117(2):259-67, 2010.
222. Lu C, Lee JJ, Komaki R, Herbst RS, Evans WK, Choy H, **Bleyer A,** Feng L, Fisch MJ. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: A randomized phase III trial. *J Natl Cancer Inst* 102(12): 859-65, 2010.
223. **Bleyer A.** Potential favorable impact of the Affordable Care Act of 2010 on cancer in young adults in the United States. *The Cancer J* 16(6):563-73, 2010.
224. **Bleyer A.** Cancers in adolescent and young adults: Latest estimates of U.S. survival and years of life affected. *J Adol Young Adult Oncol* 1(1):37-42; 2011.
225. **Bleyer A,** Lewis I, Barr R, Sender L, Albritton K. Trailblazers Roundtable. *J Adol Young Adult Oncol* 1(1):13-18, 2011.
226. Blanke C, Bot BM, Thomas DM, **Bleyer A,** Kohne CH., De Gramont MTSA, Goldberg RM, Sargent DJ. Impact of young age on treatment efficacy and safety in advanced colorectal cancer: A pooled analysis of 6,686 patients from 9 first-line phase III chemotherapy trials. *J Clin Oncol* 29(20):2781-6, 2011.
227. Stock W, Douer D, Deangelo DJ, Arellano M, Advani A, Damon L, Kovacsovic T, Litzow M, Rytting M, Borthakur G, **Bleyer A.** Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: Recommendations of an expert panel. *Leuk Lymphoma* 52(12):2237-53, 2011.
228. Hubbard J, Thomas DM, Yothers G, Green E, Blanke C, O'Connell MJ, Labianca R, Shi Q, **Bleyer A,** de Gramont A, Sargent D. Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: Findings from the Adjuvant Colon Cancer Endpoints data set. *J Clin Oncol* 30(19):2334-9, 2012.
229. **Bleyer A.** How NCCN guidelines can help young adults and older adolescents with cancer and the professionals who care for them. *J Natl Compr Canc Netw* [PMID: 22956805]. 10(9):1065-71, 2012.

230. **Bleyer A**, Ulrich C, Martin S. Young adults, cancer, health insurance, socioeconomic status, and the Affordable Care Act. *Cancer* 118 (24):6018-21;2012 [PMID: 22736148] doi:10.1002/encr.27685, online Jun 26, 2012.
231. **Bleyer A**, Welch HG. Effect of three decades of screening mammography on the incidence of breast cancer. *N Engl J Med* 367:1998-2005, (November 22) 2012. <https://www.nejm.org/doi/full/10.1056/nejmoa1206809>
Ranked 390 out of 91,063 articles published between 2010 to 2014
 by Web of Science in the *Medicine General Internal* category.
 Cited in 2,707 articles according to PubMed Central and 1,579 times according to Google Scholar
232. Johnson RH, Chien FL, **Bleyer A**. Incidence of breast cancer with distant involvement among women in the United States. *JAMA* 309(8):800-5, 2013.
233. Collins M, Conyers R, Herschtal A, Whelan J, Sydes MR, Gelderblom H, Bielack S, Wilhelm M, Ferrari S, Picci P, Smeland S, Eriksson M, Petrilli S, **Bleyer A**, Thomas DM. Benefits and adverse events in younger versus older patients receiving (neo)-adjuvant chemotherapy for osteosarcoma: Findings from a 4,403 patient meta-analysis. *J Clin Oncol* 18:2303-12, 2013.
234. **Bleyer A**. Were our estimates of overdiagnosis with mammography screening in the United States “based on faulty science”? *The Oncologist* 19:113-26, 2014.
235. Tai E, Beaupin L, **Bleyer A**. Clinical trial enrollment among adolescents with cancer: Supplement overview. *Pediatrics* 133:Supplement 3 S85-S90, 2014.
236. Tai E, Buchanan B, Eliman D, Westervelt L, Beaupin L, Lawvere S, **Bleyer A**. Understanding and addressing the lack of clinical trial enrollment among adolescents with cancer. *Pediatrics* 133:Supplement 3 S98-S103, 2014.
237. Shaw PH, Hayes-Lattin B, Johnson R, **Bleyer A**. Improving enrollment in clinical trials for adolescents with cancer. *Pediatrics* 133:Supplement 3 S109-S113, 2014.
238. Stock W, DeAngelo DJ, Douer D, Advani A, Arellano M, Rytting M, Kovacovics T, Litzow M, Damon L, Borthakur G, Luger S, Seibel N, **Bleyer A**. Applying pediatric therapeutic strategies to adults with acute lymphoblastic leukemia and lymphoma. I. Role of asparaginase. *Amer Oncol & Hemat Rev* 2014:38-46, 2014.
239. Douer D, DeAngelo DJ, Advani A, Arellano M, Litzow M, Damon L, Kovacovics T, Luger S, Seibel N, **Bleyer A**. Applying pediatric therapeutic strategies to adults with acute lymphoblastic leukemia and lymphoma. II. Comparison with adult treatment regimens, including hyper-CVAD. *Amer Oncol & Hemat Rev* 2014:47-53.
240. Chien F, Schwartz S, **Bleyer A**, Johnson R. Increasing incidence in the United States of testicular carcinoma in Hispanics. *Cancer* 120(17):2728-34, 2014.
241. Mertens AC, Yong J, Dietz A, Kreiter E, Yasui Y, **Bleyer A**, Robison LL, Wasilewski-Masker K. Conditional survival in pediatric malignancies: analysis from the comparison of Childhood Cancer Survivor Study and the Surveillance, Epidemiology and End Results data. *Cancer* 121(7):1108-17, 2015.
242. **Bleyer A**, Thomas CR, Baines C, Miller AB. Flawed assumptions used to defend screening mammography. *Cancer* 121(2):320-1, 2015.
243. **Bleyer A**, Asselin BL, Koontz SE, Hunger S. Clinical application of asparaginase activity levels following treatment with pegaspargase. *Pediatr Blood Ca* 62:1102-5, 2015.
244. Shaw P, Reed DR, Yeager N, Zebrack B, Castellino SM, **Bleyer A**. Adolescent and young adult oncology in the United States: A specialty in its late adolescence. *J Pediatr Hemat Oncol* 37(3):161-9, 2015.
245. **Bleyer A**. Screening mammography: Update and review of publications since our report in the New England Journal of Medicine on the magnitude of the problem in the United States. *Acad Radiol* 22:949-60, 2015. [http://www.academicradiology.org/article/S1076-6332\(15\)00111-7/abstract](http://www.academicradiology.org/article/S1076-6332(15)00111-7/abstract).
246. **Bleyer A**. The death burden and end-of-life intensity in adolescents and young adults with cancer. *JAMA Oncol*. 1(5):579-80, 2015.
247. **Bleyer A**. Screening Mammography: Update and review of publications since our report in the New England Journal of Medicine on the magnitude of the problem in the United States - Reply to Correspondence. *Acad Radiol* 23(1):119-23, 2016.
248. Smith AW, Seibel NL, Lewis DR, Albritton KH, Blair DG, Blanke CD, **Bleyer A**, Freyer DR, Geiger AM, Hayes-Lattin B, Tricoli JV, Wagner LI, Zebrack BJ. Next Steps for Adolescent and Young Adult Oncology Workshop: An update on progress and recommendations for the future. *Cancer* 122(7):988-99, 2016.

249. Keegan THM, Ries LAG, Barr RD, Geiger AM, Dahlke DV, Paff M, Pollock BH, **Bleyer A**, for the National Cancer Institute Next Steps for Adolescent and Young Adult Oncology Epidemiology Working Group. Comparison of cancer survival trends in the United States of adolescents and young adults with those in children and older adults. *Cancer* 122(7):1009-16, 2016.
250. Tricoli JVC, Blair DG, Anders CK, **Bleyer A**, Boardman LA, Khan J, Kummur S, Hayes-Lattin B, Hunger SP, Merchant M, Siebel NL, Thurin M, Willman CL. Biological and clinical characteristics of adolescent and young adult cancers: acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma and sarcoma. *Cancer* 122(7):1017-28, 2016.
251. **Bleyer A**, Baines C, Miller AB. Impact of screening mammography on breast cancer mortality. *Int J Ca* 138(8):2003-12, 2016.
252. Barr, RD, Ries LAG, Lewis DR, Harlan LC, Keegan THM, Pollock BH, **Bleyer WA**, for the US National Cancer Institute Science of Adolescent and Young Adult Oncology Epidemiology Working Group. Incidence and incidence trends of the most frequent cancers in adolescent and young adult Americans, including “nonmalignant/noninvasive” tumors. *Cancer* 122:1000-8, 2016.
253. Barr RD, Ries L, Ferrari A, Whelan J, **Bleyer A**. Cancer in adolescents and young adults: A narrative review of the current status and a view of the future. *JAMA Pediatr* 170(5):495-501, 2016.
254. Lee JS, DuBois SG, Coccia PF, **Bleyer A**, Ries L, Olin R, Goldsby RE. Increased risk of second malignant neoplasms in adolescents and young adults with cancer. *J Clin Oncol* 122(1):116-23, 2016.
255. Kahn JM, Keegan T, Abrahão R, **Bleyer A**, Viny AD. Racial disparities in the survival of American children, adolescents and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia and Hodgkin lymphoma. *Cancer* 122(17):2723-30, 2016.
256. Brito JP, **Bleyer A**. Impact of thyroid cancer on the incidence and survival of adolescents and young adults with cancer. *Thyroid* 26(10):1513-4, 2016. doi:10.1089/thy.2016.0170.
257. **Bleyer A**. Adolescents and young adult cancer trial participation: Will the National Community Oncology Research Program also fail? And what about the rest of us? *J Oncol Pract* 12(5):398-402, 2016.
258. Unger J, Cook E, **Bleyer A**. The role of clinical trial participation in cancer research: Barriers, evidence, and strategies. *ASCO 2016 Educational Book* 35:185-98, 2016.
259. Beaupin LK, Bostrom B, Barth MJ, Franklin I, Jaeger R, Kamath P, Schreiber B, **Bleyer A**. Pegaspargase hypersensitivity reactions: intravenous infusion versus intramuscular injection - a review. *Leuk Lymphoma* 58(4):766-72, 2017.
260. Keegan THM, **Bleyer A**, Rosenberg AS, Li Q, Goldfarb M. The impact of second primary malignancies on survival in adolescent and young adult cancer survivors. *JAMA Oncol* 3(11):1554-7, 2017.
261. **Bleyer A**. Missteps in estimates of cancer overdiagnosis. *Acad Radiol* 24(4):516-7, 2017.
262. **Bleyer A**. Synthetic turf fields, crumb rubber, and alleged cancer risk. *Sports Medicine* 47(12):2437-441, 2017. doi:10.1007/s40279-017-0735-x.
263. **Bleyer A**, Ferrari A, Whelan J, Barr RD. Global assessment of cancer incidence and survival in adolescents and young adults. *Pediatr Blood Ca* 2017;64 (online July 24, 2017). doi:10.1002/pbc.26497.
264. Araque DVP, **Bleyer A**, Brito JP. Thyroid cancer in adolescents and young adults. *Future Oncol*. 13(14):1253-61, 2017. doi:10.2217/fon-2017-0024.
265. Barr RD, **Bleyer A**. A reflection on the work of Gianni Bonadonna from the viewpoint of the global challenge of adolescents and young adults with cancer. *Tumori* 103(6):489-94, 2017. doi:10.5301/tj.5000682.
266. Barr RD, **Bleyer A**. New horizons on the landscape of AYA oncology. *Pediatr Blood Ca* 64:e26291, 2017.
267. Pirela DV, Brito JP, **Bleyer A**. Thyroid cancer in adolescents and young adults. *Future Oncol* Published Online: 15 Jun 2017 <https://doi.org/10.2217/fon-2017-0024>.
268. Ramsey LB, Balis FM, O'Brien MM, Schmiegelow K, Pauley JL, **Bleyer A**, Widemann BC, Askenazi D, Bergeron S, Shirali A, Schwartz S, Vinks AA, Heldrup J. Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance. *Oncologist* 23(1):52-61, 2018.

269. Burke MJ, Devidas M, Maloney K, Angiolillo A, Schore R, Dunsmore K, Larsen E, Mattano LA Jr, Salzer W, Winter SS, Carroll W, Winick NJ, Loh ML, Raetz E, Hunger SP, **Bleyer A**. Severe pegaspargase hypersensitivity reaction rates (grade ≥ 3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on Children's Oncology Group (COG) clinical trials. *Leuk Lymph* 59(7):1624-33, 2018. doi:10.1080/10428194.2017.1397658.
270. Siegel SE, Stock W, Johnson RH, Advani A, Muffly L, Douer D, Reed D, Lewis M, Freyer D, Shah B, Luger S, Hayes-Lattin B, Jaboin JJ, Coccia PF, DeAngelo DJ, Seibel N, **Bleyer A**. Pediatric-inspired treatment regimens for adolescents and young adults with Philadelphia-negative acute lymphoblastic leukemia: A review. *JAMA Oncol* 4(5):725-34, 2018. doi:10.1001/jamaoncol.2017.530.
271. McNeer JL, **Bleyer A**. Acute lymphoblastic leukemia and lymphoblastic lymphoma in adolescents and young adults. *Pediatr Blood Ca* 2018 June;65(6) e269892. <https://doi.org/10.1002/pbc.26989>.
272. **Bleyer A**, Keegan T. Incidence of malignant lymphoma in adolescents and young adults in the 58 counties of California with varying synthetic turf field density. *Cancer Epi* 2018 Apr;53:129-36. doi:10.1016/j.canep.2018.01.010.
273. Ferrari A, **Bleyer A**, Patel S, Gasparini P, Casanova M. The challenge of the management of adolescents and young adults with soft tissue sarcomas. *Pediatr Blood Ca* 2018;e27013. <https://doi.org/10.1002/pbc.27013>.
274. Massimino M, Evans DB, Podda M, Spinelli C, Collini P, Pizzi N, **Bleyer A**. Thyroid cancer in adolescents and young adults. *Pediatr Blood Ca* 2018 Aug;65(8):e27025. doi:10.1002/pbc.27025. <https://doi.org/10.1002/pbc.27025>.
275. Schulte RR, Madiwale MV, Flower A, Hochberg J, Burke MJ, McNeer JL, Duvall A, **Bleyer A**. Levocarnitine for asparaginase-induced hepatic injury: A multi-institutional case series and review of the literature. *Leuk Lymph* 59(10):2360-8, 2018. doi:10.1080/10428194.2018.1435873.
276. Ramsey LB, Balis FM, O'Brien MM, Schmiegelow K, Pauley JL, **Bleyer A**, Widemann BC, Askenazi D, Bergeron S, Shirali A, Schwartz S, Vinks AA, Heldrup J. Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance. *Oncologist*. 2018;23:52-61. doi:10.1634/theoncologist.2017-0243 <http://theoncologist.alphamedpress.org/content/23/1/52.long>
277. **Bleyer A**, Tai E, Siegel S. Role of clinical trials in survival progress of American adolescents and young adults with cancer – and lack thereof. *Pediatr Blood Ca* 2018 Aug;65(8):e27074. doi:10.1002/pbc.27074. <https://doi.org/10.1002/pbc.27074>.
278. Siegel SE, Muffly L, Shah B, Lewis M, Johnson H, Freyer D, Jaboin JJ, Douer D, Hayes-Lattin B, Silverman L, DeAngelo D, Coccia PF, Seibel N, **Bleyer A**. Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD versus pediatric-inspired regimens. *Am J Hemat* 93(10):1254-66, 2018. doi:10.1002/ajh.25229. <https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25229>.
279. Trama A, Bernasconi A, McCabe MG, Guevara M, Gatta G, Botta L, RARECAREnet working group, Ries L, **Bleyer A**. Is the cancer survival improvement in European and American adolescent and young adults still lagging behind that in children? *Pediatr Blood Ca* 66(1), 2018. doi:10.1002/pbc.27407. <https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.27407>.
280. **Bleyer A**, Keen JD. Continued avoidance of USPSTF guidelines for screening mammography. *J Womens Health* (Larchmt). 2018 Jul;27(7):850-3. doi:10.1089/jwh.2018.7197.
281. Johnson RH, Anders CK, Litton JK, Ruddy KJ, **Bleyer A**. Breast cancer in adolescents and young adults. *Pediatr Blood Cancer*. 2018;e27397. <https://doi.org/10.1002/pbc.27397>
282. Schore RJ, Devidas M, **Bleyer A**, Reaman GH, Winick N, Loh ML, Raetz EA, Carroll WL, Hunger SP, Angiolillo AL. Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4. *Leuk Lymph* 2019 Jul;60(7):1740-8. doi:10.1080/10428194.2018.1542146.
283. Kotwal A, **Bleyer A**, Brito J. Thyroid cancer incidence continues to rise but mortality remains stable in young, Hispanic and Black populations in the United States. *Endocrine Practice* 25(1):115-6, Jan 2019. doi:10.4158/EP-2018-0380.
284. Murray CJL, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 392(10159):1789-858, Nov 10 2018.

285. Murray CJL, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018 Epub Nov 10;392(10159):1923-94. Erratum in: *Lancet*. 12;393(10167):132, Jan 2019.
286. Kocarnik JM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups for 2010 to 2019: A systematic analysis for the Global Burden of Disease Study. *JAMA Oncol* 2022;8(3):420-444. doi:10.1001/jamaoncol.2021.6987. https://jamanetwork.com/journals/jamaoncology/fullarticle/2787350?guestAccessKey=e92bb090-1bd0-4f0f-a144-6e362d3bdceb&utm_source=jps&utm_medium=email&utm_campaign=author_alert-jamanetwork&utm_content=author-author_engagement&utm_term=1m
287. **Bleyer A**, Spreafico F, Barr R. Prostate cancer in young men: An emerging young adult and older adolescent challenge. *Cancer* 2020 Jan 1;126(1):46-57. First published September 25 2019 <https://doi.org/10.1002/cncr.32498>.
Accompanied by editorial: Why is prostate cancer incidence rising in young men. *Cancer* 25 September 2019 <https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.32497>.
288. **Bleyer A**. Magic still needed for germ cell tumor research, especially in adolescents and young adults. *J Oncol Practice* 15(8):445-6, Aug1 2019. <https://ascopubs.org/doi/full/10.1200/JOP.19.00431>.
289. Scott AR, Stoltzfus KC, Tchelebi LT, Trifiletti DM, Lehrer EJ, Rao P, **Bleyer A**, Zaorsky NG. Epidemiology of cancer in adolescents and young adults. *JAMA Open Network* 2020;3(12):e2027738. doi:10.1001/jamanetworkopen.2020.27738.
Covered by US News & World Report: www.usnews.com/news/health-news/articles/2020-12-03/cancers-in-us-teens-young-adults-have-risen-by-30-since-1970s-study
290. Barr RD, Ries LAG, Trama A, Gatta G, Steliarova-Foucher E, Stiller CA, **Bleyer WA**. A system for classifying cancers diagnosed in adolescents and young adults. *Cancer*. 2020 Nov 1;126(21):4634-4659. doi:10.1002/cncr.33041. Epub 2020 Sep 9. Erratum in: *Cancer*. 2021 Aug 15;127(16):3035-3040. <https://doi.org/10.1002/cncr.33041>
291. **Bleyer A**, Siegel S, Thomas CR. Increasing rate of unintentional firearm deaths in youngest Americans: Firearm prevalence and Covid-19 pandemic implication. *J Natl Med Association* 2021 Jun 1;113(3):265-77. <https://doi.org/10.1016/j.jnma.2020.12.005>.
292. **Bleyer A**, Spreafico F, Barr R. Causation of increased prostate cancer in young men. *Oncoscience* 2021;8:37--39. doi:10.18632/oncoscience.527. <https://www.oncoscience.us/article/527/>.
293. Cathcart-Rake EJ, Ruddy KJ, **Bleyer A**, Johnson RH. Breast cancer in adolescent and young adult (AYA) women under 40 years of age. *JCO Oncol Pract* 2021 Jan 15:OP2000793. doi:10.1200/OP.20.00793. Epub ahead of print. PMID: 33449828.
294. Cuglievan B, Berkman A, Dibaj S, Andersen C, Wang J, Livingston J, Gill J, **Bleyer A**, Roth M. Impact of lagtime, health insurance type and income status at diagnosis on the long-term survival of adolescent and young adult cancer patients. *J Adol Young Adult Oncol* 10(2):164-74, 2021.
295. Roth M, Berkman A, Anderson CA, Cuglievan B, Livingston JA, Hildebrandt M, **Bleyer A**. Improved survival of young adults with cancer following the passage of the Affordable Care Act. *Cancer Med* ePub September 30, 2021 <https://doi.org/10.1002/cam4.4292>..
296. Ingley KM, Maleddu A, Grange FL, Gerrand C, **Bleyer A**, Whelan J, Strauss SJ. Current approaches to management of bone sarcoma in adolescent and young adult (AYA) patients. *Pediatr Blood Ca* 2022 Feb;69(2):e29442. doi:10.1002/pbc.29442. Epub 2021 Nov 12. <https://onlinelibrary.wiley.com/doi/10.1002/pbc.29442>
297. Roth M, Beauchemin M, Kahn JM, **Bleyer A**. Patterns of National Cancer Institute-sponsored clinical trial enrollment in black adolescents and young adults. *Cancer Med* 2021 Nov. <http://dx.doi.org/10.1002/cam4.4292>.
298. **Bleyer A**. Important factors improving outcome of young adults with acute lymphoblastic leukemia. *Best Pract Res Clin Haemat* 2021 Dec;34(4):10132. doi:10.1016/j.beha.2021.101322. <https://www.sciencedirect.com/science/article/abs/pii/S1521692621000876?via%3Dihub>.
299. GBD 2019 Adolescent and Young Adult Cancer Collaborators: Alvarez EM, Force LM ... **Bleyer A**[†], Bhakta N[†]. [[†]Co-Senior Authors] The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* ePub December 3 2021. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(21\)00581-7/fulltext](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00581-7/fulltext).

300. **Bleyer A**, Barnes B, Finn K. United States marijuana legalization and opioid mortality epidemic during 2010-2020 and pandemic implications. *J Natl Med Association* 2022;114(4):412-425. Online 22 April 2022. <https://doi.org/10.1016/j.jnma.2022.03.004>.

301. Brock P, Meijer A, Kogner P, Ansari M, Capra M, Geller J, van den Heuvel-Eibrink M, Knight K, Kruger M, Lindemulder S, Maibach R, O'Neill A, Papadakis V, Rajput K, **Bleyer A***, Bouffet E*, Sullivan M* [*shared senior co-authorship]. Sodium thiosulfate as cisplatin otoprotectant in children: The challenge of when to use it. *Pediatr Blood Cancer*. Feb 2023. <http://doi.org/10.1002/pbc.30248>.

302. Guscott MR, Cooper SL, Bagai P, **Bleyer A**, Buddington RK, Douer D, Chong TB, Combs RR, Hylton JL, Ines-Villanueva G, Lowe JA, Pandey R, Patel AN, Howard SC. Research and care networks in acute leukemia as a model for global healthcare collaboration. *Blood* 2021;138 (Suppl 1):4966. <https://doi.org/10.1182/blood-2021-147876>.


303. **Bleyer A**. Increasing cancer in adolescents and young adults: Cancer types and causation implications. *J Adol Young Adult Oncol*. [In press]

304. The global burden of cancer attributable to risk factors, 2010–2019: A systematic analysis for the Global Burden of Disease Study 2019. *Lancet* (pending).

305. The global, regional, and national burden of adult lip, oral, and pharyngeal cancer in 204 countries and territories: A systematic analysis for the Global Burden of Disease Study 2019. *Lancet* (pending)

306. **Bleyer A**, Siegel S, Thomas CR. Firearm prevalence and lethality in America’s children and young adolescents. *Pediatrics* (pending).

307. Mani K, Lin D, Khunsriraksakul C, Kishan AU, **Bleyer A**, Wang M, Liu DJ, Zaorsky NG. Epidemiologic signatures of cancer incidence and mortality in the United States, 1975-2016 and projections to 2039 (pending).



b. Invited Articles

1. **Bleyer WA**, Drake JC, Chabner BA. Neurotoxicity and elevated cerebrospinal fluid methotrexate concentration in meningeal leukemia. In 1975 Yearbook of Cancer, Clark RL and Cumley RW (Eds), Year Book Medical Pub, Chicago, 1975, pp 25-28.
2. **Bleyer WA**. VM-26 in acute leukemia, neuroblastomas and other refractory childhood malignancies. The Candlelighters Foundation Progress Reports 2:PR5, 1982.
3. **Bleyer WA**. Clinical pharmacology and therapeutic drug monitoring of methotrexate. In Opheim K (Ed): Therapeutic drug monitoring and toxicology continuing education and quality control program, American Association for Clinical Chemistry, Washington DC, Vol 6, No II, May 1985.
4. **Bleyer WA**. Leucovorin rescue. The pharmacology and clinical use of leucovorin in antifolate chemotherapy. Burroughs Wellcome, Research Triangle Park, 1986, pp 1-24.
5. **Bleyer WA**. High-dose intravenous methotrexate with high-dose leucovorin rescue: Lessons learned from children. Proc Develop of Folates and Folate Antagonists in Cancer Chemotherapy. National Cancer Institute, Tarpon Springs, Florida, 1986, p 24.
6. Rogers PCJ, **Bleyer WA**, Coccia P, Lukens JN, Siegel S, Sather H, Hammond D. Yield of unpredicted bone-marrow relapse diagnosed by routine marrow aspiration in children with acute lymphoblastic leukemia. A report from Childrens Cancer Study Group. 1986 Year Book of Cancer, pp _.
7. **Bleyer WA**. High-dose methotrexate in the treatment of the leukemias of infancy and childhood. In Schaeffer H (Ed): Folates and Antifolates in Cancer Chemotherapy: New Perspectives, World Health Communications, New York, 1987, pp 1-13.
8. Hammond D, **Bleyer A**, Sather H. Therapeutic strategies and disease outcome for childhood acute lymphoblastic leukemia: A report from the Childrens Cancer Study Group. Proc 4th International Symposium on Therapy of Acute Leukemias, 1987, Abstract 92.
9. **Bleyer WA**. The clinical pharmacology of leucovorin and its role in 5-fluorouracil potentiation. Clinical Update: Advances in Folate Chemotherapy 1:1-15, 1989.
10. **Bleyer WA**. High-dose methotrexate in childhood acute lymphoblastic leukemia: How high should the dose be? Proc Role Clin Pharmacol Pediatr Oncol, 2nd Pharmacology Workshop Satellite to XXI SIOP Meeting, Prague, Sept 18, 1989, pp 19-33.
11. Packer RJ, **Bleyer WA**. International Symposium on Pediatric Neuro-Oncology. *Neurosciences* 14:145-66, 1989.
12. **Bleyer WA**. Pioneers in pediatric oncology (Foreword): In Taylor G (Ed): Pioneers in Pediatric Oncology, The University of Texas MD Anderson Cancer Center, 1990, pp ix-xi.
13. **Bleyer WA**. Pediatric cancers: The impact of central nervous system cancer during childhood. Proc 34th Ann Clin Conf Univ Texas MD Anderson Cancer Center, Nov 3-6, 1990, pp 71-2.
14. Reaman G, Ames M, Seibel N, Sato J, Avramis V, Madden T, **Bleyer WA**. Clinical pharmacology and new agent trials: Childrens Cancer Group. Proc Role Clin Pharmacol Pediatr Oncol, 6th Pharmacology Workshop Satellite to XXV SIOP Meeting, San Francisco, Oct 5, 1993, pp 65-72.
15. **Bleyer A**. The cure of childhood leukemia. Into the age of miracles (Book Review). *J Natl Cancer Inst* 88:375-6, 1996.
16. **Bleyer WA**. The changing epidemiology of childhood cancer in the United States. Report on National Conference. on Children's Environmental Health: Research, Practice, Prevention, Policy. Children's Environmental Health Network/Public Health Institute, 1997, pp 8-9.
17. **Bleyer WA**. Adolescents and young adults with cancer: A neglected population. ASCO 2001 Educational Book, pp. 125-32.
18. **Bleyer WA**, Barr R, Keohan ML. Adolescents and young adults with cancer: What will it take to improve outcome, ASCO 2001 Educational Book, pp. 125-40.
19. **Bleyer A**, Stock W, Coppes M, Anderson B. Clinical trial inequality: Where are the teens. *Hem/Onc Today* 2:29, April 2001

20. **Bleyer A**, Budd T, Montello M. Cancer in older adolescents and young adults: A new frontier. *POGO News*, Fall 2002, pp. 8-11.
21. **Bleyer A**. cited in Seiler C, Armstrong CL: Proceedings of the Conference on The Effects of Radiotherapy on the Brain and on Behavior Through the Life Span, San Juan, *Med Pediatr Oncol* 2003;41:460-6.
22. **Bleyer A**. Teenagers, cancer, clinical trials: Still neglected. *The Next Step*, Fall 2004, pp. 1-4, Children's Cause Cancer Advocacy.
23. **Bleyer A**. Cancer survivorship across the life span. Meet the Expert Session, American Society of Clinical Oncology 2005 Annual Meeting.
24. **Bleyer A**. Correlation of lack of participation on clinical trials and lack of progress in bone sarcoma published. *Electronic Sarcoma Update Newsletter*, June 2005.
25. **Bleyer A**. New data from the National Cancer Institute: Additional evidence that progress in survival from bone cancer in older adolescents and young adults is lagging behind. *Electronic Sarcoma Update Newsletter*, August 2005.
26. **Bleyer A**. Myth of the young and the healthy. In Giorgianni SJ, Keith J, Clair A (Eds.): *Transcendent 20s: Crossing the health care gap*. The Pfizer Journal 19(5), 2005.
27. **Bleyer A**. Cancer and Fertility: Special issues for young patients. *Cancer & Fertility Resource Guide*. A Fertile Hope Publication, 2007.
28. **Bleyer A**, Welch HG. Reply to Correspondence re: Effect of three decades of screening mammography on the incidence of breast cancer. *NEJM* 368:677-9 Feb 14, 2013 DOI:10.1056/NEJMc1215494.
29. **Bleyer A** Foreword. In Baff B (Ed.) *Our new normal: Studies of teens with Cancer*. Vol. I. Tsehai Pub., LoyolaMarymount University, Los Angeles.2019. pp xvii-xviii.

c. Editorials

1. **Bleyer WA**. Delayed toxicities of chemotherapy on childhood tissues. *Candlelighters Foundation Quarterly Newsletter* VII:III-5, 1983.
2. **Bleyer WA**. Radiotherapy versus intrathecal chemotherapy for CNS prophylaxis in childhood ALL: Article revisited. *Oncology* 3:59-69, 1989.
3. Packer RJ, **Bleyer WA**. Pediatric Neuro-Oncology. *Pediatr Neurosci* 14:113, 1989.
4. **Bleyer A**. Competitive Renewal Application and Research Plan. *CCG Quarterly* Winter 1998, 6(1): 1-19, 1998.
5. **Bleyer A**. The Children's Oncology Group (C.O.G.): Status report. *CCG Quarterly* Summer 1999, 7(3):1,6-8, 1999.
6. **Bleyer A**. State of "The Union." *CCG Quarterly* Fall 1999, 7(4): 1-8, 1999.
7. **Bleyer A**. Dr. Bleyer responds to Dr. Breslow's rebuttal to the future is ominous. *CCG Quarterly* 7(4): 9-10, 1999.
8. **Bleyer WA**. Non-Hodgkins's lymphoma (NHL) in children and adults: Contrasts and similarities with NHL in adults. *American Society of Hematology Newsletter* 1999, pp 14-5.
9. **Bleyer WA**. Point/Counterpoint [Merger of the pediatric cancer clinical cooperative groups]. *ASCO News* April, 1999, pp. 18-9.
10. **Bleyer A**. Cancer in children, teenagers, and young adults. *Candlelighter Childhood Cancer Family Alliance* Vol. 8, Nov. 2000.
11. **Bleyer A**. Chairman's report: The future is ominous. *CCG Quarterly*, Summer 1999, 1ff (cited by Parker L, Craft AW: Letter to Editor: Ominous trend in childhood cancer mortality. *Med Pediatr Oncol* 36:335, 2001).
12. **Bleyer WA**. Commentary [Practicalities and ethics of running clinical trials in paediatric oncology – the UK experience]. *Europ J Ca* 37:1399-401, 2001.
13. **Bleyer A**, et al. Helical CT and cancer risk, panel discussion. *Pediatr Radiol* 32:242-244, 2002.
14. **Bleyer A**. Young adults, cancer, clinical trials: Breakthrough? Reaching Out, *The Ulman Cancer Fund for Young Adults Fall 2004 Newsletter*, p. 2.

15. **Bleyer A**, Brundage B. Clinical research trials critical to medical progress in Central Oregon. *The Bulletin*. May 29, 2008.
16. **Bleyer A**. Making progress on Medicare. *The Bulletin* January 23, 2008.
17. **Bleyer A**. Simone's OncOpinion on *Miracle Therapy for Leukemia*, *Oncology News International* 32(6):3, 2010.
18. Kamen BA, Bertino JR, Holcenberg JS, **Bleyer WA**. Are we getting closer to using methotrexate in an optimal manner? *J Clin Oncol* 29(25):3493-4, 2011; author reply 3494-5.
19. **Bleyer A**. Current example of how lobbies ignore facts, prey on emotion, increase healthcare costs, and lead to decisions that hurt patients and their families. *The Bulletin* January 29, 2011.
20. **Bleyer A**. When do we really get around to taking on health care. In My View, [The Bulletin February 21, 2011](#).
21. **Bleyer A**. Fault lies not with our leaders, but with ourselves. In My View, [The Bulletin December 26, 2012](#).
22. **Bleyer A**. Mental illness, gun access important for doctors to note. [The Bulletin October 12, 2013](#).
23. **Bleyer A**. In and out, good and bad news, of generalizability of SWOG treatment trial results. *JNCI* 2014 Mar;106(3):dju027. Epub 2014 Mar 13.
24. **Bleyer A**. Foreword. *Amer Oncol Hemat Review* 2014:3.
25. **Bleyer A**. Suicide in Central Oregon A viable reason to reduce firearm availability? [The Bulletin March 8, 2014](#).
26. **Bleyer A**. An immunization deficit. In My View, [The Bulletin February 8, 2015](#).
27. **Bleyer A**. Management of concurrent pregnancy and acute lymphoblastic leukemia or lymphoblastic lymphoma. Comment on the article by Zaidi et al. *J Adol Young Adult Oncol* 4(2): 91-92, 2015.
28. **Bleyer A**. Supporting soccer supports the community. [The Bulletin December 19, 2015](#).
29. **Bleyer A**. Guest Column: Our nation's downward education spiral. [The Bulletin July 3, 2017](#).
30. Coutin D, **Bleyer A**. Guest Column: Help reduce Central Oregon suicides. [The Bulletin March,2 2018](#).
31. **Bleyer A**, Coutin D. Guest Column: Legislature should pass safe gun storage. [The Bulletin February 10, 2020](#).

d. Letters to the Editor and Other Correspondence

1. **Bleyer WA**. Escalator injuries in foreign countries. *Am J Dis Child* 141:14-5, 1987.
2. Jacobs SA, Johns DG and **Bleyer WA**. Methotrexate in cerebrospinal fluid. *N Engl J Med* 293:1151, 1975.
3. **Bleyer WA**, Savitch J and Poplack DG. Methotrexate in cerebrospinal fluid. *N Engl J Med* 293:1152, 1975.
4. Miser JS, Savitch JL and **Bleyer WA**. Management of *P. carinii* pneumonia. *N Engl J Med* 296:47, 1977.
5. **Bleyer WA**, Champlin RE, Chan KW, Deisseroth AB. Bone marrow transplantation for leukemia. *J Pediat* 123:492, 1993.
6. Desch MD, **Bleyer A**. Amended long-term trends in cancer incidence rates in children. *JNCI J Natl Cancer Inst* 86:1481, 1994.
7. Smith M, **Bleyer A**, Crist W, Murphy S, Sallan S. Uniform criteria for childhood acute lymphoblastic leukemia risk classification. *J Clin Oncol* 14:680-1, 1996.
8. **Bleyer WA**. Recruiting minorities into clinical trials: Towards a participant-friendly system. *J Natl Cancer Inst* 88:377, 1996.
9. Steinherz P, Gaynon P, Trigg M, Sather H, **Bleyer WA**. Cytoreduction and prognosis in childhood acute lymphoblastic leukemia (reply). *J Clin Oncol* 14: 2405-6, 1996.
10. **Bleyer WA**. A flat dose for all adult [sic] patients. *J Clin Oncol* 16:3715, 1998.
11. **Bleyer WA**. Cancer trials debate. *U.S. News & World Report*. November 29, 1999, p. 6.
12. **Bleyer WA**. Boy has little chance at cure without proven treatments. *The Cancer Letter* 26:5-6, 2000.
13. **Bleyer A**. From Long Island to Houston by rental car, in 43 hours. *The Cancer Letter* 27 (36): 5, 2001.

14. **Bleyer A**, Alberts D. Amifostine for reversal of cisplatin-induced acute renal failure. *Med Pediatr Oncol* 40:413-4, 2003.
15. **Bleyer A**. Fellows' forum forgotten? *J Clin Oncol* 18:4237, 2005.
16. **Bleyer A**. Epoetin vs. darbepoetin conundrum compromise. *J Clin Oncol* 2006;24(25):e46.
17. **Bleyer A**. "Flushing out" cytosine arabinoside from CSF to reverse neurotoxicity. *J Ped Hemat Oncol* 29:274, 2007.
18. **Bleyer A**. St. Charles patient care is fine. In My View, [The Bulletin February 3, 2006](#).
19. **Bleyer A**. Central Oregon doctors should accept more Medicare patients. In My View, [The Bulletin June 2, 2007](#).
20. **Bleyer A**, Brundage B. Clinical research trials are critical. In My View, [The Bulletin May 29, 2008](#).
21. **Bleyer A**. Despite an expert's claim, cancer still reigns as top killer. In My View, [The Bulletin March 8, 2011](#).
22. **Bleyer A**. Keep duck on the bench. My Nickel's Worth, *The Bulletin* September 18, 2011.
23. **Bleyer A**, Siegel SE, Coccia PF, Stock W, Seibel NL. Children, adolescents and young adults with leukemia: The empty half of the glass is growing. *J Clin Oncol* 30:4037-8, 2012.
24. Johnson R, Chien FL, **Bleyer A**. Incidence rate of breast cancer in young women (Reply). *JAMA* 309(23):2435, June 19, 2013.
25. **Bleyer A**. Mental illness, gun access important for doctors to note. In My View, [The Bulletin October 12, 2013](#).
26. **Bleyer A**, Asselin BL, Koontz SE, Hunger S. Reply to: Colon LB, Perissinotti A, Santarosa M, Marini BL. Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy. *Pediatr Blood Cancer*. 62:1102–1105 2015; [Online March 2, 2015](#), DOI:10.1002/pbc.25455.
27. **Bleyer A**. Reduction in late mortality after childhood cancer. *N Engl J Med* 375(3):289-392, 2016.
28. **Bleyer A**. Measure 97 could be misused for PERS deficit. In My View, [The Bulletin November 3, 2016](#).
29. **Bleyer A**, Barnes B. Opioid death rate acceleration in jurisdictions legalizing marijuana use. *JAMA Int Med*. 2018;178(9 Sept):1280-1281.
30. Siegel SE, Coccia PF, Barr R, Hays-Lattin B, **Bleyer A**. Cancer survival trends in the United States: Relatively less progress in adolescents and young adults than in younger or older patients. *JNCI*. February 21, 2019, djz019, <https://doi.org/10.1093/jnci/djz019> <https://academic.oup.com/jnci/advance-article-pdf/doi/10.1093/jnci/djz019/27942566/djz019.pdf?guestAccessKey=2d7bd8fb-70dc-41f5-8e8d-00ac6cb4b53f>.
31. **Bleyer A**. The major causes of death in children. *New Engl J Med*. 2019 (April 4);380(14):1383-1384.
32. Corcos D, **Bleyer A**. Epidemiological signatures of cancer. *New Engl J Med*. 2020 (Jan 2);382(1):96-98.
33. **Bleyer A**. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. *New Engl J Med*. 2021; 385:1919-1920.
34. **Bleyer A**. Harney County needs Measure 114. *The Oregonian*. February 23, 2023. <https://www.oregonlive.com/opinion/2023/02/readers-respond-harney-county-needs-measure-114.html>

e. Abstracts (since 2001; 149 abstracts prior to 2001)

150. **Bleyer A**, Ries L. U.S. Cancer incidence, mortality and survival: Older adolescents and young adults are lagging further and further behind. AYA 2001: Issues in Adolescent and Young Adult Leukemia. MD Anderson Cancer Center, 2001.
151. **Bleyer A**, Ries L. Incidence of leukemia from 15 to 30 Years of Age: The latest U.S. Surveillance, Epidemiology and End-Results (SEER) Data. AYA 2001: Issues in adolescent and young adult leukemia. MD Anderson Cancer Center, 2001.
152. **Bleyer A**, Ries L. U.S. Cancer incidence, mortality and survival: Young adults are lagging further behind. *Proc Am Soc Clin Oncol* 20:389a, 2002.
153. **Bleyer A**, Montello M, Budd T, Kelahan A, Ries L. U.S. cancer incidence, mortality and survival: Young adults are lagging further behind. 2002, http://www.asco.org/ac/1,1003,_12-002511-00_18-0016-00_19-001907,00.asp (select *Slides* for additional information).

154. Goy A, Sarris AH, **Bleyer A**, Duvic M, Mesina O, Dang NH, Fayad L, Hagemeister F, McLaughlin P, Pro B, Rodriguez MA, Romaguera J, Samaniego F, Younes A, Cabanillas F. Phase II study of Compound GW506U78 (AraG) in patients with T-cell and B-cell non Hodgkin lymphomas. *Proc Amer Soc Hemat* 2002, Abstr #4757.
155. **Bleyer A**, Montello M, Budd T, Ries L. CNS tumor epidemiology and outcome in the young, 2000-2009: Ten predictions for/from the United States. *Neuro-Oncology* 5:29, 2003 (www.asco.org/ac/1,1003,_12-002489-00_18-002003-00_19-00104011,00.asp).
156. Lu C, Komaki R, Herbst R, Evans WK, Smith TL, Moore CA, Kolbye S, Choi N, Choy H, **Bleyer A**. A phase III study of Æ-941 (Neovastat®) with induction chemotherapy and concomitant chemoradiotherapy for stage III non-small cell lung cancer (NCI T99-0046, RTOG 02-70, MDA 99-303): An interim overall toxicity report. *Proc Am Soc Clin Oncol* 21:663, 2003.
157. **Bleyer A**, Montello M, Budd T, Saxman S. Young adults with sarcoma: Lack of clinical trial participation and lack of survival prolongation. *Proc Am Soc Clin Oncol* 21:816, 2003.
158. Chang BB, **Bleyer AW**, Faust J, Yao J, Craig C, Ajani JA. Phase II study of bryostatatin-1 (NSC 339555) plus paclitaxel in patients with metastatic or unresectable locally advanced adenocarcinoma of stomach or gastroesophageal junction. *Proc Amer Soc Clin Oncol* 21:264, 2003.
159. Lu C, Komaki R, Herbst R, Evans WK, Smith TL, Moore CA, Kolbye S, Choi N, Choy H, **Bleyer A**. A phase III study of AE-941 (Neovastat®) with induction chemotherapy and concomitant chemoradiotherapy for stage III non-small cell lung cancer (NCI T99-0046, RTOG 02-70, MDA 99-303): An interim analysis of toxicity and response. *Lung Cancer* 41 (S2):90, 2003.
160. Tubergen DG, **Bleyer A**. Survival of 18,772 children with acute lymphocytic leukemia treated on 32 sequential clinical trials completed by the Children's Cancer Group over three decades. www.scienceandmedicine.us/research_results.htm (January 25, 2003).
161. **Bleyer A**, Montello M, Budd T. Young adults with leukemia in the United States: Lack of clinical trial participation and mortality reduction during the last decade. *Proc Am Soc Clin Oncol* 22:586, 2004.
162. Pappo A, Ries L, Herzog C, **Bleyer A**. Malignant melanoma in the first three decades of life: A report from the US Surveillance, Epidemiology and End Results (SEER) Program. *Proc Am Soc Clin Oncol* 22:721, 2004.
163. Termuhlen A, Tersak J, Hudson M, Mertens K, Gimpel N, **Bleyer A**, Yasui Y, Robison L, Oeffinger K. Health status, medical care, preventive screening, and risk behaviors of adult survivors of cancer diagnosed during adolescence. A report from the Childhood Cancer Survivor Study. *Proc Amer Soc Clin Oncol* 23:555, 2004.
164. Robison LL, Francisco L, Gaynon P, Sather H, Trigg M, Reaman G, **Bleyer WA**, Carroll W, Bhatia S. Late mortality after childhood acute lymphoblastic leukemia. *Proc Am Soc Clin Oncol*. 22:796, 2004.
165. Bendel A, Ries L, Beaty O, Bottom K, **Bleyer A**. CNS tumor epidemiology & outcome in adolescents and young adults in the United States, 1975-1998. *Proc Intl Symp Pediat Neuro-Oncol* p.51, 2004.
166. **Bleyer A**, Hag-Alshiekh M, Montello M, Budd T, Bendel A, Beaty O, O'Leary M. Older adolescents and young adults with brain tumors in the United States: Lack of clinical trial participation and of survival prolongation and mortality reduction. *Proc Intl Symp Pediat Neuro-Oncol* p.52, 2004.
167. **Bleyer A**, Montello M, Budd T. Young adults with leukemia in the United States: Lack of clinical trial participation and mortality reduction during the last decade. *Proc Am Soc Clin Oncol* 23:586, 2004.
168. Kumar A, Soares HP, Wells RJ, Khayat A, Clarke M, Hills RK, **Bleyer A**, Reaman G, Djulbegovic B. Experimental vs control interventions in cancer therapy: Which is better?—The Children's Oncology Group Experience. *J Clin Oncol*, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 6016.
169. Bhatia S, Francisco L, Gaynon PS, Sather HN, Trigg ME, Reaman G, **Bleyer WA**, Carroll WL, Robison L. Late mortality after childhood acute lymphoblastic leukemia: Follow-up of the Children's Oncology Group cohort. Internat Conf Long-Term Complications of Treatment of Children and Adolescents for Cancer, 2004.
170. Kuttesch JF, Krailo MD, **Bleyer WA**, Reaman GH. Phase II evaluation of vinorelbine in recurrent pediatric malignancies. *Proc Am Soc Clin Oncol* 23(16S):805s, 2005.
171. **Bleyer A**, Ulrich C, Martin S, Munsell M, Lange G, Taylor S. Status of health insurance predicts time from symptom onset to cancer diagnosis in young adults. *Proc Am Soc Clin Oncol* 23(16S):547s, 2005.

172. Lu C, Komaki R, Herbst R, Evans WK, Smith TL, Moore CA, Kolbye S, Choi N, Choy H, **Bleyer A**. A phase III study of Æ-941 with induction chemotherapy and concomitant chemoradiotherapy for stage III non-small cell lung cancer (NCI T99-0046, RTOG 02-70, MDA 99-303): An interim report of toxicity and response. *Proc Am Soc Clin Oncol, J Clin Oncol* 23(16S):656s, 2005.
173. Martin S, Ulrich C, Munsell M, Lange G, Taylor S, **Bleyer A**. Time to cancer diagnosis in young Americans depends on type of cancer and health insurance status. *Value in Health* 8(1):344, 2005.
174. Ulrich C, Martin S, Munsell M, Lange G, Taylor S, **Bleyer A**. Time to cancer diagnosis in older adolescents and young adults depends on type of cancer and health insurance coverage. *Assoc Ped Oncol Nurses* September 15, 2005.
175. Bendel A, Watterson J, Ries L, **Bleyer A**. Epidemiology and outcome of CNS germ cell tumors in the United States, SEER, 1975-2000; A disease of adolescents and young adults (AYA). *Second International Symposium on CNS Germ Cell Tumors*. 2005.
176. Walker D, Stiller C, Ries L, **Bleyer A**, Bendel A. Age related patterns in CNS tumor incidence with a focus on the adolescent and young adult population. *European Association of Neuro-Oncology*. Annual Meeting, 2005.
177. **Bleyer A**. Cancer in older adolescents and young adults: Reasons for lack of progress. *Pediatr Blood Cancer* 2005;45(4):376.
178. Thompson MA, Pro B, Sarris A, Hagemester FB, Goy A, **Bleyer A**, Cabanillas FF, Samaniego F, Fayad LE Results of a phase II study of 506U78 (nelarabine) in refractory indolent B-cell or peripheral T-cell lymphoma. *Blood* 2005;106:2681.
179. **Bleyer A**. The cancers of adolescence and young adulthood that present the greatest survival challenge. *International Society of Pediatric Oncology (SIOP) Annual Meeting*, Geneva, Switzerland, September 2006.
180. Wang SJ, Fuller CD, Luh JL, Thomas CR, **Bleyer A**. Older adolescents and young adults with cancer: conditional survival deficit. *Proc 48th Annual ASTRO (Amer Soc Therap Radio Oncol) Meeting*. 2006;S135-6.
181. Wang SJ, Fuller CD, Thomas CR, **Bleyer WA**. Older adolescents and young adults with cancer: Conditional survival deficit, *Health Services/Outcomes Research in Radiation Oncology Symposium*, 2006; __:__.
182. Viny A, Hilden J, Stallion A, **Bleyer WA**. The racial disparity gap in pediatric leukemia and lymphoma survival has been eliminated in children but not in older adolescents and young adults. *Blood* 108, 2006.
183. **Bleyer A**: Effect of 9-11 on U.S. national cancer clinical trials accrual and lack of effect of National Cancer Institute budget increases (and impact-benefit of the Adolescent and Young Adult Initiative): *J Clin Oncol* 25(18S):334s, 2007.
184. Advani A, Earl M, Douer D, Rytting M, **Bleyer A**. Toxicities of intravenous pegasparginase (Oncaspar) in adults with acute lymphoblastic leukemia. *Blood (ASH Annual Meeting Abstracts)* 110: 2811, Nov 2007.
185. **Bleyer A**. Older adolescents and young adults with acute lymphoblastic leukemia (ALL) in the United States: From the lowest to highest death rate and number of deaths - More rationale for the CALBG-SWOG-ECOG C10403 trial based on COG AALL0232. *J Clin Oncol* Abstract 2008.
186. Ferrari A, **Bleyer A**. Accrual to clinical trials: Adolescents with bone sarcomas on the Italian cooperative group AIEOP protocols. *International Society of Pediatric Oncology (SIOP) Annual Meeting*, Berlin, September 2008.
187. **Bleyer A**, Friedman S, Finnigan S, Montello M, Budd T, Anderson B, Trimble E. Turnaround in adolescent and young adult cancer treatment trial activity and early evidence for national mortality reduction benefit in the United States. *International Society of Pediatric Oncology (SIOP) Annual Meeting*, Berlin, September 2008.
188. Rytting M, Earl M, Douer D, Muriera B, Advani A, **Bleyer A**. Toxicities in adults with acute lymphoblastic leukemia treated with regimens using intravenous pegasparginase. *Blood (ASH Annual Meeting Abstracts)* 112: 1924, Nov 2008.
189. **Bleyer A**, Friedman S, Finnigan S, Montello M, Budd T, Anderson B, Trimble E. Association of adolescent and young adult cancer treatment trial activity with a national mortality reduction benefit in the United States. *Proc Am Soc Clin Oncol, J Clin Oncol* 27(15S):349s, 2009.

190. Wessler JM, Crouch G, **Bleyer A**, Merino M. Lagtime to oncologic diagnoses: A comparison between military and non-military healthcare systems. Amer Soc Pediatr Hemat Oncol 23rd Annual Meeting. *Pediatr Blood Cancer* 54(6):Abstract #195, 2010.
191. **Bleyer A**. AYA Medicine: International momentum derived from the perspective of childhood leukemia. Proc Nordic Soc Paediat Haemat Oncol 29th Ann Meeting, Turku, Finland, May 21-24, p. 26, 2011.
192. Indelicato D, **Bleyer A**. Clinical trial availability compared to incidence rates for adolescent and young adult cancer. *J Clin Oncol* 29: suppl; abstr 6119, 2011.
193. **Bleyer A**. Exponentially increasing incidence of childhood leukemia in young adults. *Chemother Foun Symp*. November 9, 2011, NYC.
194. **Bleyer A**, DiPardo B, Thomas CR. Breast cancer mortality reduction in the U.S. during 1969-2010 was independent of screening mammography in its nine geographically disperse SEER regions: More evidence for less benefit of screening mammography. *Amer Soc Radiat Oncol*. 55th Annual Meeting Abstr 2761, 2013. <http://astro2013.abstractsnet.com/aposter.wcs?entryid=010903>. Accessed October 7, 2013.
195. **Bleyer A**. Adolescents and young adults with cancer: Unique biology? *International Society of Pediatric Oncology (SIOP) Annual Meeting Plenary Session*, Toronto, Canada, October 2014.
196. Schore R, Devidas M, **Bleyer A**, et al. Plasma asparaginase activity and asparagine depletion in patients with all treated with pegaspargase: Results from COG AALL07P4. *J Clin Oncol* 34, 2016 (suppl; abstr 10508).
197. Schore R, Devidas M, **Bleyer A**, Reaman GH, Winick N, Lebedinsky C, Zhang H, Koppensteiner H, Loh M, Raetz E, Winick NL, Carroll WL, Hunger SP, Angiolillo AL. Anti-pegaspargase, anti-calaspargase pegol, and anti-polyethylene glycol antibody incidence in high risk acute lymphoblastic leukemia patients receiving pegaspargase or calaspargase pegol and associated anaphylactic or hypersensitivity reaction rates: Results from Children's Oncology Group (COG) Study AALL07P4. *Blood* 2016;28;1365.
198. Levine O, Zbuk K, **Bleyer A**. Topographical incidence and survival analysis of gastrointestinal tract cancer in adolescent and young adults compared with older adults in the United States. American Gastroenterological Association Institute, American Society for Clinical Oncology, the American Society for Radiation Oncology, *Society of Surgical Oncology 2017 Gastrointestinal Cancers Symposium*. Abstract 545, 2017.
199. Madiwale MV, Schulte R, Hochberg J, McNeer JL, Messinger YH, **Bleyer A**. Asparaginase-induced hepatic injury and role of levocarnitine in management: a multi institutional case series. *Pediatr Blood Ca*. American Society of Pediatric Hematology-Oncology (ASPHO) Abstract, 2017.
200. Brito JP, **Bleyer A**. Thyroid cancer incidence continues to rise in young, Hispanic and African-American populations in the United States. *Endocrinology*. 90th Annual Meeting of the *Endocrine Society*, 2017. Abstract SH04-6.
201. Neuwelt EA, Lindemulder S, Knight K, Fu R, **Bleyer A**, Raykov R, Brock P. Hearing chemoprotection with sodium thiosulfate in children, adolescents and young adults with standard risk medulloblastoma. *International Symposium on Pediatric Neruo-Oncology (ISPNO) Annual Meeting*, Denver, Colorado, June-July, 2018.
202. Kahn J, Keegan THM, Muffly L, Alvarez E, Winestone L, **Bleyer A**. Disparities in cancer-related mortality and long-term survival in adolescent and young adults with Hodgkin lymphoma: A population-level analysis across the United States. *Amer Soc Hemat* 60th Annual Meeting and Exposition (December 1-4, 2018) San Diego, CA.
203. Brito JP, **Bleyer A**. Impact of thyroid cancer on the overall incidence and survival of adolescents and young adults with cancer. *Thyroid* 2018;26(10). Published Online: 2016 (Oct 1). <https://doi.org/10.1089/thy.2016.0170>.
204. Chien F, Johnson RH, **Bleyer A**. Continued increase in AYA breast cancer with distant involvement among women in United States after 6 additional years of analysis. *3rd Global AYA Cancer Congress*, 2018. Sydney, Australia.
205. Ewart M, **Bleyer A**. Adolescents and young adults with cancer continue to face disparities in rate of change in five-year survival. Univ. North Texas Research Appreciation Day. 2020.
206. Siembida E, **Bleyer A**, Roth M Racial disparities in adolescent and young adult cancer clinical trial enrollment. *Amer Soc Clin Oncol (ASCO) Annual Meeting*. 2020.
207. Corcos D, **Bleyer A**. Mammography-induced breast cancers in older women. Facing the Challenges of Cancer Prevention and Early Detection. 2nd International DFKZ Conference on Cancer Prevention. Sept 17-18, 2020.

208. Alvarez E, **Bleyer A**, Keegan T, et al. The global burden of adolescent and young adult cancers in 2019: an analysis of the Global Burden of Disease Study 2019. *International Society of Pediatric Oncology (SIOP) Annual Meeting*, Virtual Congress, October 2020.
209. Ewart MJ, Bowman WP, **Bleyer A**, Rutledge LJ. Adolescents and young adults with cancer continue to face disparities in rate of change in five-year survival. Research Appreciation Day. University of North Texas Health Sciences Center. March 2021.
210. Guscott M, Bagai P, **Bleyer A**, Buddington R, Cooper S, Douer D, Chantada G, Chong T, Combs R, Hylton J, Inez-Villanueva G, Lowe J, Pandey R, Patel A, Howard S. Research and care networks in acute lymphoblastic leukemia as a model for global healthcare collaboration. *Amer Soc Hemat Annual Meeting* 2021.
211. Hwang M, Guscott M, Bernhardt MB, Livingston JA, Ramsey L, Heldrup J, Etienne C, Schaff, LR, **Bleyer A**, Howard S. Improved use of folinic acid as a rescue medication for high-dose methotrexate. *International Society of Pediatric Oncology (SIOP) Annual Meeting Plenary Session*, __, __, October 2023.

f. Other Articles

1. **Bleyer WA**. An ovarian teratoma in a 4-year-old girl. *Correspondence Society of Surgeons* 6:7, 1983.
2. **Bleyer WA**. Remaining problems in the staging and treatment of childhood leukemia. *Cope* Nov 1988, pp 27-28.
3. **Bleyer A**. Odyssey 9-11 (trip home from Long Island the day after 9-11). *The Cancer Letter* October, 2001.
4. **Bleyer A**. *c* is for *cure*. Taking the lead against childhood cancer, *National Childhood Cancer Foundation* 2000, pp. 20-26.
5. **Bleyer WA**. Light brilliance in the life battle (preface). In *Life in the Light Battles*, The Lady Pao Children's Cancer Centre, Prince of Wales Hospital, Department of Pediatrics, The Chinese University of Hong Kong, 2001, pp 14-18.
6. **Bleyer WA**. Cancer brings distinct challenges to young adults and older adolescent patients. *Hem/Onc Today* 3:40-42, 2002.
7. **Bleyer A**. Gap creates a true lost generation. Mind the Gap. Insights (on how we're helping teens live with cancer). Melissa Living Legacy Foundation. 1;1-5, 2003.
8. **Bleyer A**, Ries L. in Hampton T. Cancer treatment's trade-off. *JAMA* 294;167-8, 2005.
9. **Bleyer A**. Cancer in teenagers: What every parent needs to know. *Coping Magazine* July/August 2006, p.36.
10. **Bleyer A**. The National Cancer Institute's Adolescent and Young Adult Oncology Report: Fertility Addressed as an important late-effect for AYAs. *Fertile Hope Newsletter* Fall, 2006.
11. **Bleyer A**. US breast cancer mortality is consistent with European data. *BMJ* 2011; 343:d5630 doi:10.1136/bmj.d5630 (Published 6 September 2011) www.bmj.com/content/343/bmj.d5630.full?ijkey= KsUxBqNyqzR80rK&keytype=ref
12. Louie R, **Bleyer WA**. Will new funding improve Alzheimer's dementia outcomes? The Health Care Blog. <http://thehealthcareblog.com/blog/2016/04/20/will-new-funding-improve-alzheimers-dementia-outcomes>. Accessed July 29, 2016.
13. **Bleyer A**. Could the rising rates of colorectal cancer in AYAs be linked to HPV infection? By Jo Cavallo, *ASCO Post*. October 25, 2017 <http://www.ascopost.com/issues/october-25-2017/could-the-rising-rates-of-colorectal-cancer-in-ayas-be-linked-to-hpv-infection/>
14. **Bleyer A**. The growth of pediatric oncology and optimal care for pediatric acute lymphoblastic leukemia, August 7, 2019. <https://www.journalofclinicalpathways.com/news/growth-pediatric-oncology-and-optimal-care-pediatric-acute-lymphoblastic-leukemia>. Accessed August 8, 2019.
15. **Bleyer A**, Barnes B. Contribution of marijuana legalization to the U.S. opioid mortality epidemic: Individual and combined experience of 27 states and District of Columbia. MedRxiv BMJ, Yale, Cold Spring Harbor Preprint Server for the Health Sciences, doi:<https://doi.org/10.1101/19007393>. <https://www.medrxiv.org/content/10.1101/19007393v1>. Accessed September 29, 2019.
16. **Bleyer A**, Siegel S, Thomas CR.. Increasing firearm deaths in the youngest Americans: Ecologic correlation with firearm prevalence. MedRxiv BMJ, Yale, Cold Spring Harbor Preprint Server for the Health Sciences,

doi:<https://doi.org/10.1101/1900919>. <https://www.medrxiv.org/content/10.1101/19009191v2> Accessed October 18, 2019.

17. **Bleyer A**, Siegel SE, Thomas CR. Increasing firearm deaths in the youngest americans: ecologic correlation with firearm prevalence, <https://www.medrxiv.org/content/10.1101/19009191v2>. Accessed June 14, 2020.
18. **Bleyer A**, Barnes B. Contribution of marijuana legalization to the U.S. opioid mortality epidemic: Individual and combined experience of 27 States and District of Columbia. <https://www.medrxiv.org/content/10.1101/19007393v2>. Accessed June 14, 2020.

g. Books and Monographs

1. **Bleyer WA**, Byrne TN. Leptomeningeal Cancer in Leukemia and Solid Tumors. In Haskell CM (Ed): *Current Problems in Cancer*, Year Book Med Publ, Chicago, 1988, Vol XII, No 4, pp. 181-238.
2. Packer RJ, **Bleyer WA**, Pochedly C (Eds). *Pediatric Neuro-Oncology: New Trends in Neuro-Oncology*, Philadelphia, Harwood Academic, 1992.
3. Eden TOB, Barr R, **Bleyer A**, Whiteson M (Eds). *Cancer and the Adolescent*, 2 Ed., Blackwell/BMJ Publishing, 2005 [294 pages].
4. **Bleyer WA**, O'Leary M, Barr R, Ries LAG (Eds). *Cancer Epidemiology in Adolescents and Young Adults 15 to 29 Years of Age, including SEER Incidence and Survival, 1975-2000*. National Cancer Institute, NIH Pub. No. 06-5767, Bethesda MD, June 2006 [205 pages].
5. Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults with Cancer. <http://www.cancer.gov/types/aya/research/ayao-august-2006.pdf>. Accessed December 11, 2020.
6. Closing the gap: A strategic plan Addressing the Recommendations of the Adolescent and Young Adult Oncology Progress Review Group. <http://images.livestrong.org/downloads/flatfiles/what-we-do/our-actions/pnp/LS-young/LAF-YAA-Report.pdf>, 104 pages. Accessed November 17, 2015.
7. **Bleyer A**, Barr RD, Albritton KH, Phillips M, Siegel S (Eds). *Cancer in Adolescents and Young Adults*, Springer Berlin Heidelberg, 2007 [73 authors from 9 countries on 4 continents, 534 pages, 199 figures, 90 tables].
8. Barr R, **Bleyer A** (Eds). Impact of Malignant Disease on Young Adults (Part I). *Semin Oncol* 36(3):193-287, June 2009 [26 authors from 6 countries on 3 continents, 9 articles, 32 figures, 13 tables, 95 pages].
9. **Bleyer A**, Barr R (Eds). Impact of Malignant Disease on Young Adults II. *Semin Oncol* 36(3): 380-488, October 2009 [24 authors, 9 articles, 43 figures, 21 tables, 108 pages].
10. **Bleyer A**, Barr RD, Ries L, Ferrari A, Whelan J (Eds). *Cancer in Adolescents and Young Adults*, [2nd Edition](#). Springer International, Switzerland, 2017 [129 authors from 11 countries on 5 continents, 849 pages, 245 figures, 129 tables, 3,817 references, 4.8 lb (\$140,544 worth in weight of gold on June 10, 2022)].

59,327 chapter downloads as of September 2021.

h. Book Chapters

1. **Bleyer WA**. Principles of drug therapy in newborn infants and children. In Smith DS (Ed): *Introduction to Clinical Pediatrics*, 2nd ed, Philadelphia, WB Saunders Co, 1977, pp 37-42.
2. **Bleyer WA** and Feusner JH. Anemia and bleeding. In Smith, DS (Ed): *Introduction to Clinical Pediatrics*, 2nd ed, Philadelphia, WB Saunders Co, 1977, pp 397-403.
3. Bernstein IL, Wallace MJ, Bernstein ID, **Bleyer WA**, Chard RL and Hartmann JR. Learned food aversions as a consequence of cancer treatment. In van Eys J, Seelig MS and Nichols BL (Eds): *Nutrition and Cancer*, New York, SP Medical & Scientific Books, 1977, pp 159-64.
4. Chard RL, Hartmann JR, Bernstein ID, **Bleyer WA** and Johnson FL. Acute childhood leukemia. In Conn HF (Ed): *Current Therapy*, Philadelphia, WB Saunders Co, 1978, pp 309-15.
5. **Bleyer WA** and Poplack DG. Clinical studies on the central nervous system pharmacology of methotrexate. In Pinedo, HM and Boelsma, E (Eds): *Clinical Pharmacology of Anti-Neoplastic Drugs*, Amsterdam, Elsevier/North Holland Biomedical Press, 1978, pp 115-31.

6. Poplack DG, **Bleyer WA** and Wood JH. A primate model for the study of central nervous system pharmacokinetics of antineoplastic agents. In Whitehouse J and Kay HEM (Eds): *CNS Complications of Malignant Disease*, London, MacMillan Press, Ltd, 1979, pp 397-406.
7. Gangji D, Cohen L, **Bleyer WA**, Vigersky R, Glaubiger D, and Poplack DG. Methotrexate CNS pharmacokinetics in combination chemotherapy. In Whitehouse J and Kay HEM (Eds): *CNS Complications of Malignant Disease*, London, MacMillan Press, Ltd, 1979, pp 407-12.
8. **Bleyer WA**, Griffin TW. White matter necrosis, mineralizing microangiopathy, and intellectual abilities in survivors of childhood leukemia: Associations with central nervous system irradiation and methotrexate therapy. In Gilbert HA, Kagen AR (Eds): *Radiation Damage to the Nervous System*, New York, Raven Press, 1980, pp 115-74.
9. **Bleyer WA**. Antineoplastic agents, in Yaffe S: *Pediatric pharmacology: Therapeutic principles in practice*, New York, Grune & Stratton, 1980, pp 349-77.
10. Poplack DG, **Bleyer WA** and Horowitz ME. Pharmacology of antineoplastic agents in cerebrospinal fluid. In Wood JH (Ed): *Neurobiology of Cerebrospinal Fluid*, Vol 1, New York, Plenum Publish, 1980, pp 561-78.
11. Riccardi R, **Bleyer WA** and Poplack DG. Enhancement of delivery of antineoplastic drugs into cerebrospinal fluid. In Wood JH (Ed): *Neurobiology of Cerebrospinal Fluid*, Vol 2, New York, Plenum Publ, 1980, pp 453-66.
12. Kersey JH, LeBien TW, Gajl-Peczalska K, Nesbit M, Jansen J, Kung P, Goldstein G, Sather H, Coccia P, Siegel S, **Bleyer A** and Hammond D. Acute lymphoblastic leukemia/lymphoma: cell markers define phenotypic heterogeneity. In Knapp W, Proc Leuk Marker Conf, 1980, p .
13. **Bleyer WA**. Therapeutic drug monitoring of methotrexate and other antineoplastic drugs. In Baer DM and Dita WR (Eds): *Interpretations in Therapeutic Drug Monitoring*, Chicago, Am Soc Clin Path, 1981, pp 169-81.
14. Gangji D, Reaman GH, Cohen SR, **Bleyer WA** and Poplack DG. Elevated myelin basic protein in the cerebrospinal fluid of acute lymphoblastic leukemia patients with leukoencephalopathy. In Hildebrand J, Gangji D (Eds): *Treatment of Neoplastic Lesions of the Nervous System*. Oxford & New York, Pergamon Press, 1982, pp S1-S5.
15. **Bleyer WA**. Central nervous system leukemia. In Gunz F, Henderson ES (Eds): *Leukemia*, 4th Ed, New York, Grune & Stratton, 1983, pp 865-911.
16. Coccia PF, **Bleyer WA**, Siegel SE, Lukens JN, Gross S, Miller DR, Littman PF, Sather HN and Hammond GD. Development and preliminary findings of Children's Cancer Study Group Protocols (#161,162,163) for low, average, and high risk acute lymphoblastic leukemia in children. In Murphy S, Gilber JR (Eds): *Leukemia Research - Advances in Cell Biology and Treatment*, North Holland, Elsevier Publ, 1983, pp 241-50.
17. **Bleyer WA**, Level C, Sather DJ, Niebrugge DJ, Coccia PF, Siegel S, Littman PS, Leikin SL, Miller DR, Chard RL Jr. and Hammond GD. Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal-methotrexate dosage regimen. In Mastrangelo R, Poplack DG, Riccardi R (Eds): *Central Nervous System Leukemia*, Boston, Martinus Nijhoff Publ, 1983, pp 27-38.
18. **Bleyer WA**. Clinical pharmacology: Guidelines for the clinical use of methotrexate. In Hall RR (Ed): *Pharmanual, A Comprehensive Guide to the Therapeutic Use of Methotrexate in Bladder Cancer*, Chicago, PharmaLibri, 1983, pp 50-69.
19. **Bleyer WA**. Acute lymphoid leukemias. In Pochedly C (Ed): *Cancer Therapy in Children*, Thorofare, Slack, 1983, pp 1-15.
20. Ignoffo RJ and **Bleyer WA** (Associate Editors). Antineoplastic agents. In Taylor WJ, Caviness MHD (Ed): *Textbook for the Clinical Application of Therapeutic Drug Monitoring*, Abbott Laboratories, Irving, Texas, 1986, pp. 397-399.
21. **Bleyer WA**. Some clinical features of childhood leukemia of special significance for molecular biology. In Gale RP, Golde DW (Eds), *Recent Advances in Leukemia and Lymphoma*, New York, Alan R Liss, 1987, pp 465-479.
22. **Bleyer WA**. An overview of adverse late effects of cancer chemotherapy in children. In Poplack DG, Massimo L, and Cornaglia-Ferraris P (Eds). *The Role of Pharmacology in Pediatric Oncology*, Boston/Dordrecht/Lancaster, Martinus Nijhoff, 1987, pp. 207-15.
23. Mahler P, Griffin B, Geyer JR, **Bleyer WA**. Chemoradiotherapy interactions and the blood-brain barrier. In Neuwelt E (Ed): *Implications of the Blood-Brain Barrier and Its Manipulation: Volume 2, Clinical Aspects*, New York, Plenum Publ, 1988, pp 373-88, 1989.

24. Blatt J, **Bleyer WA**. Late effects of childhood cancer and its treatment. In Pizzo PA, Poplack DG (Eds): *Principles and Practice of Pediatric Oncology*, JB Lippincott, Philadelphia, 1989, pp. 1003-25.
25. **Bleyer WA**. Central nervous system leukemia. In Henderson ES and Lister TA (Eds): *Leukemia*, 5th Ed, Philadelphia, WB Saunders, 1990, pp 733-768.
26. **Bleyer WA**. The impact in the United States and the world of central nervous system cancer during childhood. In: Packer RJ, **Bleyer WA**, Pochedly C (Eds): *Pediatric Neuro-oncology: New Trends in Neuro-Oncology*, Philadelphia, Harwood Academic, 1992, pp. 1-7.
27. **Bleyer WA**, Poplack DG, Balis FM. Pharmacokinetics of commonly used anti-leukemic agents in children. In Kobayashi N, Akera T, Mizutani S (Eds): *Childhood Leukemia: Present Problems and Future Prospects*, Kluwer Academic, 1991, Boston, pp 149-55.
28. Blatt J, Copeland DR, **Bleyer WA**. Late effects of childhood cancer and its treatment. In Pizzo PA, Poplack DG (Eds): *Principles and Practice of Pediatric Oncology*, Second Edition, JB Lippincott, Philadelphia, 1993, pp. 1091-114.
29. Moore IM, Packer RJ, Karl D, **Bleyer WA**. Adverse effects of cancer treatment on the central nervous system. In Schwartz CL et al: *Survivors of Childhood Cancer: Assessment and Management*, St. Louis, Mosby, 1994, pp. 81-96.
30. Blatt J, Copeland DR, **Bleyer WA**. Late effects of childhood cancer and its treatment. In Pizzo PA, Poplack DG (Eds): *Principles and Practice of Pediatric Oncology*, Third Edition, JB Lippincott, Philadelphia, 1997, pp. 1303-30.
31. **Bleyer A**. Value of cancer registries. In Hutchinson CL, Roffers SD, Fritz AG (Eds.). *Cancer Registry Management: Principles & Practice*, Kendall/Hunt, 1997, Lenexa KS, pp xv-xvi.
32. Zipf TF, Berg SL, Roberts WM, Poplack DG, **Bleyer WA** Childhood Leukemias. In Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE (Eds). *Clinical Oncology*, Second Edition, Churchill Livingstone, New York, 2000, pp 2402-34.
33. **Bleyer WA**. Acute lymphoblastic leukemia. In Herzog CE, Pratt CB: Therapy of cancer in children. *Clinical Insights*, New York, 2000, pp. 8-10.
34. Reaman GH, **Bleyer A**. Infants and adolescents with cancer: Special considerations. In Pizzo PA, Poplack DG (Eds): *Principles and Practice of Pediatric Oncology*, Fourth Edition, JB Lippincott, Philadelphia, 2001, pp. 409-28.
35. Dreyer ZE, Blatt J, **Bleyer A**. Late effects of childhood cancer and its treatment. In Pizzo PA, Poplack DG (Eds): *Principles and Practice of Pediatric Oncology*, Fourth Edition, JB Lippincott, Philadelphia, 2001, pp. 1431-62.
36. **Bleyer A**. Principles of diagnosis. In Behrman RE, Kliegman RM, Jenson HB (Eds.) *Nelson's Textbook of Pediatrics*. 17th Ed, 2003, Saunders, Philadelphia, pp. 1684-8.
37. **Bleyer A**: Principles of treatment. In Behrman RE, Kliegman RM, Jenson HB (Eds.) *Nelson's Textbook of Pediatrics*. 17th Ed, 2003, Saunders, Philadelphia, pp. 1988-94.
38. Tubergen DG, **Bleyer A**. The leukemias. In Behrman RE, Kliegman RM, Jenson HB (Eds.) *Nelson's Textbook of Pediatrics*. 17th Ed, 2003, Saunders, Philadelphia, pp. 1694-8.
39. **Bleyer A**, Albritton K. Special considerations for the young adult and adolescent. In Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Holland JF, Frei E (Eds): *Holland-Frei: Cancer Medicine*. Ed. 6, 2003, B. C. Decker, pp. 2414-22.
40. Stiller C, **Bleyer A**. Epidemiology. In Walker D, Perilongo G, Punt J, Taylor R (Eds): *Brain and Spinal Tumours of Childhood*, 2004, Arnold, London, pp. 3-49.
41. Ater J, **Bleyer A**. Medulloblastoma. In Pinkerton R, Philip T, Fervers B (Eds), *Evidence-based Paediatric Oncology*, BMJ Books, London, 2005, pp 139-170.
42. Ater J, **Bleyer A**. Gliomas. In Pinkerton R, Philip T, Fervers B (Eds), *Evidence-based Paediatric Oncology*, BMJ Books, London, 2005, pp 170-188.
43. **Bleyer WA**, Albritton K. Malignant diseases in adolescents. In Greydanus DE, Patel DR, Pratt HD (Eds). *Essential Adolescent Medicine*. McGraw-Hill Medical Publishing Division, New York, 2006, pp. 391-410.

44. **Bleyer A.** Lack of participation of young people with cancer in clinical trials: Impact on the U.S. In Eden TOB, Barr R, **Bleyer A**, Whiteson M (Eds): *Cancer and the Adolescent 2*, Blackwell/BMJ Publishing, 2005, pp. 35-42.
45. Reaman GH, **Bleyer A.** Infants and adolescents with cancer: Special considerations. In Pizzo PA, Poplack DG (Eds): *Principles and Practice of Pediatric Oncology*, Fifth Edition, JB Lippincott, Philadelphia, 2006, pp. 452-75.
46. **Bleyer A**, Viny A, Barr R. Introduction. In: **Bleyer WA**, O'Leary M, Barr R, Ries LAG (Eds): Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival, 1975-2000. National Cancer Institute, NIH Pub. No. 06-5767, Bethesda MD, June 2006; also available at www.seer.cancer.gov/publications/aya.
47. **Bleyer A**, Hag-Alshiekh M, Pollock B, Ries LAG. Methods. In: **Bleyer A**, Viny A, Barr R: Introduction. In **Bleyer WA**, O'Leary M, Barr R, Ries LAG (Eds): Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, including SEER Incidence and Survival, 1975-2000. National Cancer Institute, NIH Pub. No. 06-5767, Bethesda MD, June 2006; also available at www.seer.cancer.gov/publications/aya.
48. Herzog C, Pappo A, Bondy M, **Bleyer A**, Kirkwood J. Malignant melanoma. In: **Bleyer WA**, O'Leary M, Barr R, Ries LAG (Eds): Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, including SEER Incidence and Survival, 1975-2000. National Cancer Institute, NIH Pub. No. 06-5767, Bethesda MD, June 2006; also available at www.seer.cancer.gov/publications/aya.
49. Casillas J, Ross J, Keohan ML, **Bleyer A**, Malogolowkin M. Soft tissue sarcomas. In: **Bleyer A**, O'Leary M, Barr R, Ries LAG (Eds): Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, including SEER Incidence and Survival, 1975-2000. National Cancer Institute, NIH Pub. No. 06-5767, Bethesda MD, June 2006; also available at www.seer.cancer.gov/publications/aya.
50. Waguespack S, Wells S, Ross J, **Bleyer A.** Thyroid cancer. **Bleyer A**, In: **Bleyer A**, O'Leary M, Barr R, Ries LAG (Eds): Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, including SEER Incidence and Survival, 1975-2000. National Cancer Institute, NIH Pub. No. 06-5767, Bethesda MD, June 2006; also available at www.seer.cancer.gov/publications/aya.
51. Bleyer W, Barr R. Highlights and challenges. In **Bleyer A**, O'Leary M, Barr R, Ries LAG (Eds): Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, including SEER Incidence and Survival, 1975-2000. National Cancer Institute, NIH Pub. No. 06-5767, Bethesda MD, June 2006; also available at www.seer.cancer.gov/publications/aya.
52. **Bleyer A**, Albritton K. Cancer in the young adult and adolescent. In Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Holland JF, Frei E (Eds): Holland-Frei: *Cancer Medicine*. Ed. 7, 2006, B. C. Decker, Hamilton, Ontario, Canada, pp. 2028-36.
53. **Bleyer A**, Albritton K, Ries LAG, Barr R. Introduction. In **Bleyer A**, Barr RD, Albritton KH, Phillips M, Siegel S (Eds): *Cancer in Adolescents and Young Adults*, Springer Verlag, Berlin Heidelberg New York, 2007, pp. 1-26.
54. **Bleyer A**, Budd T, Montello M. Older adolescents and young adults with cancer and clinical trials: Lack of participation and progress in North America. In **Bleyer A**, Barr RD, Albritton KH, Phillips M, Siegel S (Eds): *Cancer in Adolescents and Young Adults*, Springer Verlag, Berlin Heidelberg New York, 2007, pp. 71-82.
55. Birch J, **Bleyer A.** Epidemiology and etiology of cancer in adolescents and young adults. In **Bleyer A**, Barr R, Albritton K, Phillips M, Siegel S (Eds): In **Bleyer A**, Barr RD, Albritton KH, Phillips M, Siegel S (Eds): *Cancer in Adolescents and Young Adults*, Springer Verlag, Berlin Heidelberg New York, 2007, pp. 39-70.
56. Nachman J, Masera G, **Bleyer A.** Acute lymphoblastic leukemia. In **Bleyer A**, Barr R, Albritton K, Phillips M, Siegel S (Eds): In **Bleyer A**, Barr RD, Albritton KH, Phillips M, Siegel S (Eds): *Cancer in Adolescents and Young Adults*, Springer Verlag, Berlin Heidelberg New York, 2007, pp. 83-98.
57. Trippett T, Oberlin O, **Bleyer A**, Constine L. Hodgkin lymphoma. In **Bleyer A**, Barr RD, Albritton KH, Phillips M, Siegel S (Eds): *Cancer in Adolescents and Young Adults*, Springer Verlag, Berlin Heidelberg New York, 2007, pp. 111-26.
58. Patte C, **Bleyer A**, Cairo M. Non-Hodgkin lymphoma. In **Bleyer A**, Barr RD, Albritton KH, Phillips M, Siegel S (Eds): *Cancer in Adolescents and Young Adults*, Springer Verlag, Berlin Heidelberg New York, 2007, pp. 127-51.
59. Leahy M, **Bleyer A.** Non-germ-cell genitourinary tract tumors. In **Bleyer A**, Barr RD, Albritton KH, Phillips M, Siegel S (Eds): *Cancer in Adolescents and Young Adults*, Springer Verlag, Berlin Heidelberg New York, 2007, pp. 249-58.

60. Herzog C, **Bleyer A**, Pappo A. Malignant melanoma. In **Bleyer A**, Barr RD, Albritton KH, Phillips M, Siegel S (Eds): *Cancer in Adolescents and Young Adults*, Springer Verlag, Berlin Heidelberg New York, 2007, pp. 272-92.
61. Phillips M, Arun B, **Bleyer A**. Breast cancer. In **Bleyer A**, Barr RD, Albritton KH, Phillips M, Siegel S (Eds): *Cancer in Adolescents and Young Adults*, Springer Verlag, Berlin Heidelberg New York, 2007, pp. 293-310
62. **Bleyer A**, Barr R, Phillips M, Siegel S, Albritton K. Challenges and opportunities – The way forward. In **Bleyer A**, Barr RD, Albritton KH, Phillips M, Siegel S (Eds): *Cancer in Adolescents and Young Adults*, Springer Verlag, Berlin Heidelberg New York, 2007, pp. 505-17.
63. **Bleyer A**, Ritchey AK. Principles of treatment. In Behrman RE, Kliegman RM, Jenson HB (Eds.) *Nelson Textbook of Pediatrics*. 18th Ed, 2007, Saunders, Philadelphia, pp. Chapter 488, 1721-1721.
64. Tubergen DG, **Bleyer A**, Ritchey AK. The leukemias. In Behrman RE., Kliegman RM, Jenson HB (Eds.) *Nelson Textbook of Pediatrics*. 18th Ed, 2007, Saunders, Philadelphia, Chapter 489, pp. 1721-1729.
65. Dreyer Z, Indelicato DJ, Reaman GH, **Bleyer WA**. Infants and adolescents with cancer: Special considerations. In Pizzo PA, Poplack DG (Eds): *Principles and Practice of Pediatric Oncology*, Sixth Edition, JB Lippincott, Philadelphia, 2011, pp. 446-466.
66. Barr B, Ries L, Ferrari A, Whelan J, **Bleyer B**. Adolescent and young adult oncology: historical and global perspectives. In Bleyer A, Barr RD, Ries L, Whelan J, Ferrari A (Eds): *Cancer in Adolescents and Young Adults*, 2nd Edition. Springer International, Switzerland, 2017, pp. 1-6.
67. Ries L, Trama A, Nagata K, Gatta G, Botta B, **Bleyer A**. Cancer incidence, survival and mortality among adolescents and young adults. In Bleyer A, Barr RD, Ries L, Whelan J, Ferrari A (Eds): *Cancer in Adolescents and Young Adults*, 2nd Edition. Springer International, Switzerland, 2017, pp. 7-42.
68. Tricoli J, **Bleyer A**, Anninga J, Barr B. The biology of adolescent and young adult cancers. In Bleyer A, Barr RD, Ries L, Whelan J, Ferrari A (Eds): *Cancer in Adolescents and Young Adults*, 2nd Edition. Springer International, Switzerland, 2017, pp. 43-68.
69. McNeer J, **Bleyer A**, Conter V, Stock W. Acute lymphoblastic leukemia. In Bleyer A, Barr RD, Ries L, Whelan J, Ferrari A (Eds): *Cancer in Adolescents and Young Adults*, 2nd Edition. Springer International, Switzerland, 2017, pp. 151-176.
70. Massimino M, Podda M, Spinelli C, **Bleyer A**. Thyroid cancer. In Bleyer A, Barr RD, Ries L, Whelan J, Ferrari A (Eds): *Cancer in Adolescents and Young Adults*, 2nd Edition. Springer International, Switzerland, 2017, pp. 203-230.
71. Hayes-Lattin B, **Bleyer A**. Testicular cancer. In Bleyer A, Barr RD, Ries L, Whelan J, Ferrari A (Eds): *Cancer in Adolescents and Young Adults*, 2nd Edition. Springer International, Switzerland, 2017, pp. 319-334.
72. Walker W, Bendel A, Stiller C, Indelicato D, Smith S, Murray M, **Bleyer A**. Central nervous system tumors. In Bleyer A, Barr RD, Ries L, Whelan J, Ferrari A (Eds): *Cancer in Adolescents and Young Adults*, 2nd Edition. Springer International, Switzerland, 2017, pp. 335-382.
73. Leahy M, Spreafico F, **Bleyer A**. Cancer of kidney, bladder, and prostate. In Bleyer A, Barr RD, Ries L, Whelan J, Ferrari A (Eds): *Cancer in Adolescents and Young Adults*, 2nd Edition. Springer International, Switzerland, 2017, pp. 429-452.0
74. **Bleyer A**. Other carcinomas. In Bleyer A, Barr RD, Ries L, Whelan J, Ferrari A (Eds): *Cancer in Adolescents and Young Adults*, 2nd Edition. Springer International, Switzerland, 2017, pp. 477-499.
75. Barr R, Ries L, Ferrari A, Whelan J, **Bleyer A**. Conclusions, perspectives, and future considerations. In Bleyer A, Barr RD, Ries L, Whelan J, Ferrari A (Eds): *Cancer in Adolescents and Young Adults*, 2nd Edition. Springer International, Switzerland, 2017, pp. 819-825.
76. **Bleyer A**. Adolescent and young adult (AYA) patients with acute lymphoblastic leukemia and lymphoblastic lymphoma: Epidemiology, survival trends, and optimal therapy. In Karpp JE, Emadi A. (Eds): *Acute Leukemia: An Illustrated Guide to Diagnosis and Treatment*. Springer International, Switzerland, 2017, pp.192-204.
77. **Bleyer A**, Ries L, Ferrari A, Whelan J, Barr R. Adolescents and young adults with cancer. In Devita, Lawrence, and Rosenberg's *Cancer: Principles & Practice of Oncology*, 11th Edition, 2019, pages 1617-1631.

78. **Bleyer A**, Ferrari A, Osborn M, Ries L, Barr R. Adolescents and young adults with cancer. In Devita, Lawrence, and Rosenberg's *Cancer: Principles & Practice of Oncology*, 12th Edition, 2023, pages _-_.

i. Manuals, Teaching Aids See full CV*